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ABSTRACT OF THESIS 
 
 
 
 
MINIMUM INHIBITORY CONCENTRATIONS OF  
TWO COMMON FOOD PHENOLIC COMPOUNDS AND THEIR  
EFFECT ON THE MICROBIAL ECOLOGY OF SWINE FECES IN VITRO  
 
 
 Feeding sub-therapeutic levels of antibiotics to livestock has been associated with 
development and spread of antibiotic resistant bacteria.  The present experiment was conducted 
to investigate the effect of antibiotic alternatives (caffeic acid, chlorogenic acid, and carbadox) 
on the microbial ecology of swine feces in vitro.   
Minimum inhibitory concentrations of caffeic and chlorogenic acids were determined for 
several pathogens using macrobroth and agar dilution techniques.  Gram-negative bacteria were 
not inhibited.  Caffeic acid inhibited four Staphylococcus aureus strains at 200 ppm or less, and 
two Clostridium perfringens strains at 300 ppm.  Chlorogenic acid inhibited all S. aureus strains 
at 500 ppm, and one C. perfringens strain at 400 ppm.  
Effects of antibiotic alternatives on fecal microbial ecology were determined using an in 
vitro incubation.  Caffeic acid lowered total anaerobes, Bifidobacteria, Escherichia coli, and 
percent E. coli (p<0.01).  Chlorogenic acid lowered total anaerobes, Bifidobacteria, and 
lactobacilli (p<0.01), and increased acetate concentration (p<0.0001).  Carbadox lowered total 
anaerobes, Bifidobacteria, E. coli, and coliforms (p<0.01), and lowered acetate, propionate, 
butyrate, valerate, and total volatile fatty acid concentrations (p<0.01).  It can be concluded that 
addition of caffeic acid, chlorogenic acid, or carbadox effected bacterial and chemical 
components of the microbial ecology of swine feces. 
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CHAPTER 1 
Introduction 
 Shortly after the introduction of antibiotics to the public, bacteria resistant to antibiotics 
emerged.  Antibiotic resistance is a self-preservation technique inherent to the microorganism or 
acquired through microbial genetics.  Complications associated with resistance include cross-
resistance, multiple-drug resistance, increased virulence, and difficulty in treating disease.   
The development of resistance occurs in two main reservoirs, humans and animals.  
Humans often misuse antibiotic therapy.  Antibiotics are also frequently used in the livestock 
industry.  They have been used as feed supplements for over 50 years at sub-therapeutic levels to 
promote growth.  Scientists have linked this practice to the development and spread of resistance 
in humans. 
Resistant bacteria can be transported from human to human, animal to animal, and animal 
to human through direct or indirect contact, including the consumption of food.  Another 
problem emerges if the resistant bacteria are pathogens that cause foodborne illness.  Each year, 
an estimated 5.2 million people suffer from foodborne bacterial gastroenteritis (Mead et al., 
1999).  Salmonella, Campylobacter, Escherichia coli, and Clostridium perfringens are leading 
causes of bacterial foodborne illnesses.  Antibiotic resistance in these pathogens may induce 
increased survivability and toxin production, resulting in prolonged illness or heightened severity 
of disease. 
There are several ways to address the growing problem of antibiotic resistance. 
Discovery and creation of new antibiotics by scientists occur, but may not be practical.  The role 
of antibiotic use in humans and animals can be altered.  The prudent use of antibiotics and 
improved hygiene can decrease the development and spread of resistance.  In addition, when 
antibiotics are removed from livestock diets, level of resistance decreases.  For these reasons, 
The European Union (EU) has already banned several growth promoting antibiotics used in 
animal feeds.   
Antibiotics are confirmed to improve growth performance in livestock compared to non-
antibiotic supplementation, translating into a bigger profit for the farmer.  However, growing 
public concern about antibiotic resistance is forcing farmers to seek out alternatives.  
Alternatives to antibiotics can be implemented without a lengthy approval process through the 
Food and Drug Administration (FDA).  Well-studied alternatives include probiotics and 
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prebiotics, which have demonstrated improved growth characteristics and disease prevention.  
Yet, few studies exist on the effect of functional foods or herbs included in livestock diets.   
To be included in a diet, a feed or feed supplement must be proven safe as well as 
improving growth performance or preventing disease.  This can be accomplished through 
scientific studies.  To develop a true understanding how diet effects an animal and the food it 
produces, studies must be done on many levels.  One level includes specific chemicals found in 
food and how they may effect the animal in a variety of ways. 
The chemical composition of a food plays a major role in its functionality.  Phenolic 
compounds are a major group of biologically active chemicals found in plants (phytochemicals), 
and have been found to have antimicrobial, antioxidant, and anticarcinogenic activities.  Some of 
the most common phenolic compounds found in foods of plant origin are the hydroxycinnamic 
acids (HCA), including caffeic acid (CFA) and chlorogenic acid (CGA).   
Phytochemicals may have an effect of the microbial ecology of the gastrointestinal tract.  
The microbial ecology of animals plays a major role in the overall health of the animal.  Healthy 
animals have decreased illnesses and improved growth characteristics.  Understanding how diet 
affects microbial ecology is important to livestock producers as well as consumers.  Therefore, 
the objectives of this study were: 
1) To determine the minimum inhibitory concentrations of caffeic acid and chlorogenic 
acid against selected Gram-negative and Gram-positive pathogens. 
2) To determine how caffeic acid and chlorogenic acid effect the fecal microbial ecology 
of swine in vitro.   
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CHAPTER 2 
Literature Review 
 
Antibiotic Resistance 
Antibiotics were discovered as early as 1888 in Germany but were toxic to mammals and 
unstable.  Although Alexander Fleming discovered penicillin in Britain in 1929, it was not 
introduced to the public until 1942.  Shortly after, in 1945 Fleming warned of selecting for 
mutant bacteria resistant to penicillin (Levy, 1992).  Since then, antibiotics have been widely 
used for the prevention and treatment of disease in humans.  Pharmaceutical companies have 
provided large quantities for human and animal use.  However, bacterial resistance to antibiotics 
threatens the ability of doctors to keep the human population healthy. 
Definitions.  Antibiotics are not novel biological agents, but very common microbial 
products.  Using a strict definition, an antibiotic is a chemical produced by a microorganism that 
has the ability to inhibit the growth of bacteria, or kill bacteria and other microorganisms 
(Scholar and Pratt, 2000).  This is a self-preservation technique used by many microbes.  This 
definition has broadened to include synthetic and semi-synthetic antibiotics created by scientists.   
Yet, the definition of an antibiotic fails to consider other materials such as plants and the 
compounds derived from them.  These materials are considered chemotherapeutic agents 
(Jurgens, 1997), and can also be called antimicrobials.  In the end, the results can be the same, 
bacteriostatic or bactericidal effects.  Bacteriostatic compounds inhibit bacterial replication and 
growth, while bactericidal compounds cause bacterial cell death and lysis (Scholar and Pratt, 
2000).  Bacteriostatic drugs do not kill invading pathogens, but they allow the host’s immune 
system to catch up in the infection battle.  Growth of invading pathogens is put on hold giving 
the host’s immune system more time to respond and rid the body of infection. 
Mechanisms of resistance.  Antibiotics work by targeting specific areas of the bacterial 
cell: preventing proper cell wall synthesis, interfering with nucleic acid or protein production, 
inhibiting chromosome replication and function, interference of folate metabolism, and 
compromising membrane permeability (Scholar and Pratt, 2000).  Ideally, an antibiotic will only 
affect the infecting organism and will not harm host cells (selective toxicity).   
 Antibiotic resistance occurs when a bacterium is not sensitive to an antibiotic and 
continues to grow.  Some bacteria have intrinsic resistance.  The microorganism may lack a 
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specific drug receptor, or have protective characteristics such as the Gram-negative outer 
membrane which prevents the antibiotic from entering the cell (Scholar and Pratt, 2000).  Gram-
positive bacteria do not have this protective outer membrane (Hancock, 1997). 
Resistance may also be acquired.  The bacterium identifies an antibiotic as an 
environmental toxin.  The microbe may initially be sensitive to an antibiotic, but undergoes a 
change in order to become less sensitive or completely insensitive.  The change occurs through 
an assortment of biochemical mechanisms including decreased uptake of the drug, increased 
efflux of the drug, enzymatic inactivation of the drug, and altered target receptor (Scholar and 
Pratt, 2000). 
Acquired resistance may occur by a mutation in the bacterial genome or through 
obtaining genetic information for resistance from another bacterium.  Hundreds of different 
genes encode for biochemical mechanisms of resistance.  Resistance may occur to only one 
antibiotic; still, one antibiotic can also trigger multi-drug resistance (George and Levy, 1983; 
Levy et al., 1976).   
Development of resistance.  The main reservoirs of antibiotic resistant bacteria include 
humans and animals.  Causes for development of resistance include over-prescription by doctors, 
prophylactic treatment (prevention of disease) of hospitalized patients, misuse of antibiotics by 
patients at home, and use of antibiotics in agriculture.  Today, doctors are better educated on 
consequences of over-prescription.  Doctors are prescribing antibiotics less and educating their 
patients, making them more aware that following directions for the prescription is important 
(Williams and Heymann, 1998).  However, the use of antibiotics in the livestock industry is 
commonplace around the globe and consequently contributes to the development and spread of 
antibiotic resistance. 
 Therapeutic and subtherapeutic antibiotic use in animals accounts for half of the world’s 
antibiotic output (Perreten et al., 1997).  Feeding antibiotics to animals was commercially 
introduced in 1959.  In animal production, high doses of antibiotics are applied to feed, drinking 
water, or by injection for short periods of time to cure disease.  The more common use is in low 
doses (below therapeutic levels) administered in feed for a long period of time to prevent disease 
and improve performance.  The result is a decrease in the amount of feed required to produce a 
unit of gain in body weight, and lower morbidity and mortality rates.  This translates into greater 
profit for the farmer (Strauch, 1987c).   
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Exposure to antibiotics in high or low doses creates resistance in bacteria.  Some bacteria 
return to previous sensitivity, while others remain unchanged after hundreds of generations in 
antibiotic-free media (Strauch, 1987c).  However, bacterial ecology of mammals is very 
complex.  Skin/hide, respiratory, and gastrointestinal microbes include bacteria, fungi, protozoa, 
and viruses.  These microbes are biologically linked, and when one group is affected, the others 
are as well.  Resistance creates a selective pressure on the bacterial populations.  The organisms 
with resistance will continue to reproduce, and the ones lacking resistance will perish.  In the 
presence of the antibiotic, this selective pressure causes a shift towards resistant microflora of the 
host. 
Intensively managed animals, such as swine, receive more antibiotics than other animals, 
such as cattle or sheep on pasture.  They carry large numbers of antibiotic resistant Escherichia 
coli in their intestinal flora (up to 90%), and they become established components of the gut and 
persist even in the absence of antibiotics (Linton et al., 1976). 
Spread of resistance.  The spread of resistance occurs through transfer of genetic 
material from a resistant bacterium to a sensitive one.  Genetic material may include plasmids, 
transposons, integrons, phages, and other elements capable of mobility.  
Plasmids are circular, extrachromasomal (not on the chromosome), double-stranded 
DNA.  They have the ability to replicate independently of the host bacterial cell. Most resistance 
in bacteria is plasmid-mediated, and one plasmid usually encodes for resistance to more than one 
antibiotic (Salyers and Shoemaker, 1994).  Specifically, R-plasmids encode for antibiotic 
resistance.  They can be transferred to other bacteria through the process of conjugation.  
Conjugation is a “mating” process used by bacteria to transfer genetic information from the 
donor to a recipient (Strauch, 1987c).   
Transposable elements (transposons) are mobile extrachromasomal linear DNA that can 
recombine into the genome at random or at particular “hotspots.”  Transposons can occur on the 
chromosome or on plasmids.  They often encode for enzymes involved in antibiotic resistance.  
The ability of a transposon to jump from one site to another (plasmid to plasmid, plasmid to 
chromosome, chromosome to plasmid) does not require help from the bacterial cell.  The 
transposon’s genes encode for enzymes needed for its own mobilization.  Once the transposon is 
on a conjugative plasmid, it can be transferred to another bacterium.  There can be multiple 
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transposons on a single plasmid (Lewin, 2002).  Other transposons have the ability to conjugate 
themselves (Salyers and Shoemaker, 1994). 
More recently discovered, integrons are linear segments of extrachromasomal DNA.  
Unlike transposons, they integrate at a specific site with an 8 base pair consensus sequence.  
They require plasmid-encoded enzymes to integrate into DNA and rely on the plasmid’s 
promoter (a region of DNA involved in the initiation of transcription) to activate resistance 
genes.  Several integron resistance genes can be inserted end to end and be controlled by one 
promoter.  (Salyers and Whitte, 1994). 
Another important mechanism of transfer is the bacteriophage.  A bacteriophage is a 
virus that infects bacteria (also known as a phage).  The phage binds to the outer bacterial 
membrane and injects its DNA (or RNA) into the cell.  Once inside the cell, the genetic material 
can incorporate itself into the chromosome.  Inserted phage DNA could contain a transposon 
encoding for antibiotic resistance as well as other virulence factors (Lewin, 2000; Salyers and 
Whitte, 1994).   
There are numerous examples of bacteria able to transfer resistance, even in the absence 
of antibiotics.  Virginiamycin resistant Enterococcus faecium isolated from pigs and broilers was 
able to transfer its resistance to a sensitive E. faecium (Hammerum, et al., 1998).  The transfer, or 
spread, is not limited to specific bacterial strains or even species.  Resistance can be transferred 
from one genera to another.  Resistant Salmonella was able to transfer its resistance to an E. coli 
(Tessi et al., 1997).  Gram-negative E. coli was able to transfer resistance into the Gram-positive 
Clostridium perfringens (Kaufmann et al., 1996).  The multi-drug resistant Lactococcus lactis 
spp. lactis K214 isolated from a raw milk soft cheese was able to transfer its resistance to 
Enterococcus faecalis (Perreten et al., 1997).  The ability of a non-pathogen to transfer its 
resistance to pathogens that can cause disease is an obvious concern to humans.    There is even 
an example of trans-kingdom transfer of antibiotic resistance from an E. coli to the yeast 
Saccharomyces cerevisiae (Heinemann and Sprague, 1989). 
Resistance can spread directly from animal to animal or animal to human.  Bacteria can 
be excreted from an animal in a number of ways: mucosal secretions, feces, urine, milk, blood, 
and sperm (Strauch, 1987b).  Bacteria and/or their spores may also become airborne (Strauch, 
1987a).  A farmer that works directly with livestock faces several microbial hazards.  First, if the 
bacterium is a pathogen, he risks illness.  Second, if the bacterium is resistant to antibiotics, the 
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resistance can be transferred to his own microflora.  Farmers may also be in direct contact with 
animal feed that contains antibiotics.  People working with farm animals have a higher 
percentage of antibiotic resistant E. coli in their intestinal microflora compared to the non-
farming community (Levy et al., 1976).  
Finally, resistance can spread from animal to food to human.  Food is the direct link 
between microflora of an animal and the non-farming community.  As previously discussed, 
antibiotic resistant bacteria have been isolated from animals as well as their food products.  For 
meat products, it is not possible to slaughter an animal without contaminating the carcass with 
intestinal and skin/hide microflora (Jackson et al., 1997).  Linton et al. (1977) were able to show 
resistant bacteria from chickens were carried along the food chain and colonized in man. 
Significance of antibiotic resistant bacteria.  Virulence is the degree to which a 
pathogen can cause disease.  Antibiotic resistance has been associated with virulence factors.  In 
one particular strain of E. coli isolated from piglets with diarrhea, genes controlling the 
production of enterotoxins were located on the same plasmid that encoded for tetracycline, 
streptomycin, and sulfonamide resistance (Gyles et al., 1977).  The H2 plasmid carries resistance 
to chloramphenicol, kanamycin, streptomycin, and tetracycline.  This plasmid was linked to 
enhanced survivability in calf intestines when tetracycline was introduced in the diet (Timoney 
and Linton, 1982). 
Antibiotic resistance can not only increase the severity of disease it also makes treatment 
of diseases more difficult.  Staphylococcus aureus can infect any part of the human body and is 
the main cause of bovine mastitis (Tueber, 1999).  The most common cause of urinary tract 
infection is E. coli (Strauch, 1987c).  Resistant strains are more difficult to eliminate and 
treatment becomes more costly. 
Although some antibiotics fed to animals are not the same ones specifically prescribed to 
humans, there are other complications such as cross-resistance.  For example, vancomycin is 
used for human therapy, while avoparcin is used in animal husbandry.  Both antibiotics have the 
same mode of action by inhibiting cell wall synthesis, and resistance to one can render resistance 
to the other.  The resistant bacteria can be transferred to humans by physical contact with the 
animal or through food (Witte, 1998). 
Different components of the food chain are intricately intertwined (Figure 1).  An 
example of this occurred in the former East Germany.  The antibiotic streptothricin was used as a  
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Figure 1.  Network of Resistance.  Adapted from Witte, W.  1998.  Medical Consequences of 
Antibiotic Use in Agriculture.  Science.  279: 996-997.  Main reservoirs of antibiotic resistant 
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growth promoter in pigs from 1982 to 1990.  In 1984, resistance to the antibiotic was found in E. 
coli isolated from the gut flora of farm employees and their family members.  By 1985, resistant 
E. coli were found in the urban population, milk and meat products, sick animals, and patients 
with urinary tract infections.  Before the end of application in the early 1990’s, resistance was 
found in bacteria causing the illnesses salmonellosis and shigellosis (Tschape, 1994).  
Interactions between human, animal, plant and environmental bacterial ecologies lead to an 
increase in the occurrence of antibiotic resistant pathogens.  The threat of infection from a 
resistant, untreatable foodborne pathogen is increasing and becoming a significant risk in daily 
life (Mazel and Davies, 1999). 
 
Foodborne Pathogens 
 Each year, an estimated 14 million people suffer from foodborne bacterial gastroenteritis 
(Mead et al., 1999).  Food contains multiple nutrients that may support the growth of many 
pathogenic (disease-causing) bacteria.  Gastroenteritis is a general term and refers to acute 
infectious diarrhea.  The diarrhea usually lasts less that 2 weeks and may be accompanied by 
nausea, vomiting, fever, and abdominal pain (Schlossberg, 2001).  From 1991 to 1993, bacterial 
foodborne illnesses cost Americans $2.9-$6.7 billion dollars annually, and the number of 
antibiotic resistant pathogens rises each year (CDC, 1998).  A major challenge to human health 
is antibiotic resistance in foodborne pathogens.  The resistance can develop by exposure to an 
antibiotic or occur through transfer of resistance genes from another bacterium as discussed in 
the previous section.  Some of the major microorganisms causing foodborne illnesses are 
discussed here.   
Salmonella.  Salmonella species are Gram-negative rods that occur widely in nature.  
They are commonly found in the intestinal tracts of humans and animals.  The organisms are 
excreted in feces and may be transported to numerous places, including water and food (Jay, 
1996). 
The genus Salmonella is divided into only 2 species, S. enterica and S. bongori.  There 
are 6 subspecies within S. enterica (Table 1).  Nearly all disease causing serotypes belong to this 
subspecies (Fierer and Guiney, 2001).  Currently there are 1,478 serovars belonging to S. 
enterica subsp. enterica (Popoff et al., 2001).  In this text, serovars are treated as species.  For 
example, S. enterica subsp. enterica serovar Typhimurium will be referred to as S. typhimurium. 
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Table 1.  Current number of Salmonella serovars.a 
Species Number 
S. enterica 
     subsp. enterica 1478
     subsp. salamae 498
     subsp. arizonae 94
     subsp. diarizonae 327
     subsp. houtenae 71
     subsp. indica 12
S. bongori 21
Total 2501
aFrom Popoff et. al., 2001. 
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 Salmonella species cause salmonellosis (gastroenteritis) and are responsible for an 
estimated 1.5 million bacterial foodborne cases each year.  They cause an estimated 25% of 
hospitalizations and 31% of deaths caused by all foodborne illnesses, including bacterial, 
parasitic, and viral cases (Mead et al, 1999).  Salmonella typhimurium and S. enteritidis are the 
most common isolated foodborne serovars (CDC, 2002).  Foods associated with Salmonella 
involve raw meats, eggs, dairy products, raw fruits and vegetables, and water (CDC, 2001).  
Infective dose may be very low depending on age and health of host as well as differences 
among bacterial strains.  In New York city, an outbreak of salmonellosis was due to non-dairy 
ice cream, and 150 viable salmonellae per gram of food were found (Armstrong et al., 1970).  
Symptoms usually appear in 12-72 hours and include nausea, vomiting, abdominal pain, chills, 
headache, and diarrhea and lasts 4-7 days (Schlossberg, 2001). 
Most cases do not require treatment of antibiotics unless the infection does not clear up or 
the infection spreads.  Complications following salmonellosis include septicemia (blood 
infection), reactive arthritis, and Reiter’s syndrome (Petersen et al., 1996).  Reiter’s syndrome 
consists of urethritis (or cervicitis), conjunctivitis, and arthritis (Dworkin et al, 2001). 
Resistance is important because of increased virulence and inability to treat the disease in 
humans and animals.  Multi-drug resistance was found in 96% of S. typhimurium isolates from 
swine in North Carolina (Gerbreyes et al., 2000).  A particularly virulent stain, S. typhimurium 
DT104, carries phage DNA with a typical multidrug-resistance pattern to ampicillin, 
chloramphenicol, streptomycin, sulfonamides, and tetracyclines.  This phage type has also shown 
resistance to trimethoprim, spectinomycin, and ciprofloxacin (Teuber, 1999).  Incidence of this 
multidrug-resistant organism is on the rise.  In 1979-1980, occurrence of S. typhimurium isolates 
with a five-drug resistance pattern was 0.6%.  In 1996, 34% of isolates displayed this pattern 
(Glynn et al., 1998). Fluoroquinolones are often prescribed to ill patients.  However, an outbreak 
of DT104 in Denmark in 1998 proved difficult.  The bacteria isolated had reduced sensitivity to 
fluoroquinolones.  Out of 25 confirmed cases, 11 were hospitalized and 2 patients died (Mølbak 
et al., 1999). 
Escherichia coli.  Escherichia coli is a Gram-negative rod and is present as intestinal 
microflora of humans and animals.  Fecal contamination of foods and water are responsible for 
E. coli gastroenteritis (Jay, 1996).   
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Five virulence types are recognized as a possible cause of gastroenteritis: 
enterohemorrhagic E. coli (EHEC), enteroinvasive E. coli (EIEC), enteropathogenic E. coli 
(EPEC), enterotoxigenic E. coli (ETEC), and more recently enteroaggregative E. coli (EAggEC) 
(Levine, 1987).  Foods associated with E. coli gastroenteritis include beef, unpasteurized milk 
and juice, raw fruits and vegetables, salad dressings, salami, and contaminated water (CDC, 
2001). 
EPEC and EIEC generally do not produce toxins.  EPEC strains cause diarrhea in 
children under 1 year of age (Donnenberg and Kaper, 1992), and EIEC strains can cause 
voluminous bloody or non-bloody diarrhea (Levine, 1987).  ETEC strains produce enterotoxins 
resulting in profuse watery diarrhea with a very sudden onset, and is a well known cause of 
traveler’s diarrhea (Levine, 1987).  Onset of symptoms for EPEC, EIEC, and ETEC is between 
12 and 72 hours, and infective doses range between 105-107 viable cells (Eley, 1996).  EAggEC 
strains produce enterotoxin (Savarino et al., 1991) and cause persistent diarrhea that lasts for 
over 2 weeks (Bhan et al., 1989). 
EHEC strains produce Shiga-like toxins (SLT) and can cause hemorrhagic colitis (bloody 
diarrhea), severe abdominal cramps, nausea, and vomiting.  Symptoms appear after an incubation 
period of 1-8 days and last for 5-10 days (CDC, 2001).  The most well known strain, EHEC 
serotype O157:H7, was not recognized as a cause of human illness until 1982 (Bean and Griffin, 
1990).  Infective dose for EHEC O157:H7 is thought to be low, as few as 10 organisms causing 
illness (Keene et al., 1994; Willshaw et al., 1994).   
Hemolytic uremic syndrome (HUS) is an illness that can develop from infection of SLT 
producing bacteria and may be associated with antibiotic therapy.  The syndrome consists of 
hemolytic anemia, thrombocytopenia, and acute renal failure.  Wong et al. (2000) conducted a 
study of children infected with E. coli O157:H7 gastroenteritis.   HUS developed in 14%, half of 
which had previously received antibiotics.  They concluded that antibiotic treatment of children 
with this type of infection increases the risk of developing HUS.    
An estimated 270,000 illnesses per year are attributed to all E. coli infections, 74,000 
from O157:H7, 37,000 from other Shiga-toxin producing E. coli (STEC) and 159,000 from non-
STEC.  However, STEC strains account for an estimated 5% of hospitalizations and 4% of 
deaths related to all foodborne illnesses, including bacterial, viral, and parasitic infections (Mead 
et al., 1999). 
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Antimicrobial therapy is generally not effective and could increase virulence.  Antibiotic 
resistant E. coli have shown an increased ability to colonize the intestines (Timoney and Linton, 
1982).  Antibiotic treatment of EHEC infections is very controversial.  SLT is encoded for by 
bacteriophage DNA (Schmidt, 2001).  Antibiotics induce the phage lytic cycle via the SOS 
pathway (Fuchs et al., 1999).  The SOS response is induced by DNA damage or inhibition of 
DNA replication.  The lytic cycle involves mass-production of more phages, as well as SLTs.  
When cells lyse, phages and toxins are released, resulting in more damage to the patient (Neely 
and Friedman, 1998).  Olaquindox and carbadox are used as growth promoters in the livestock 
industry and have been shown to increase toxin production in the same manner.  This may 
influence transfer of virulence genes between microbes of the animal, increasing development 
and spread of new SLT producing bacteria (Köher et al., 2000). 
There is evidence of increasing numbers of antibiotic resistant E. coli O157:H7 strains.  
Isolates collected between 1984-1987 were all sensitive to antibiotics.  From 1989-1991, 7.4% of 
strains isolated were resistant to streptomycin, sulfisoxazole, and tetracycline (Kim et al., 1994).  
Not only is virulence increased, but the prevalence of this pathogen in food animals is increased.   
Campylobacter jejuni.  Campylobacter jejuni is a microaerophilic Gram-negative curved 
rod and is a common inhabitant of the intestinal tract of animals.  This particular bacterium is 
quite fastidious and requires reduced oxygen (approximately 5%) and about 10% carbon dioxide 
for good growth in the laboratory.  They are difficult to grow and stress such as exposure to air, 
drying, low pH, heating, and freezing hinder recovery (BAM, 1998).  They do not grow at 25°C, 
and the optimum for growth is 42°C.  Despite these hurdles, they can survive at 4°C for 2-4 
weeks (Blaser et al., 1980).  
Campylobacter infections cause campylobacteriosis (campylobacter enteritis or 
gastroenteritis).  The majority of cases (over 90%) are attributed to C. jejuni.  Other 
Campylobacter recognized as a cause of gastroenteritis include C. coli, C. fetus, and C. 
upsaliensis (McClellan et al., 2002).  Foods associated with Campylobacter include poultry, 
unpasteurized milk, and contaminated water (CDC, 2001).  However, C. jejuni has been isolated 
from many sources, including hamburger, cattle feces, sheep carcasses, and swine carcasses 
(Blaser, 1982).  Symptoms of campylobacteriosis include watery diarrhea that may contain 
blood, fever, abdominal pain, nausea, headache, and muscle pain.  Incubation period is 1-7 days 
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and the symptoms last about a week (Schlossberg, 2001).  Infective dose is small, 800 cells being 
able to cause disease depending on bacterial strain (Black et al., 1988).  
Surveillance has been limited due to a couple of factors.  First, the organism requires 
special laboratory equipment to provide the proper environment for recovery and growth.  In 
addition, this bacterium was not reported as a cause of foodborne illness until 1980 (Bean and 
Griffin, 1990).  It is now thought that C. jejuni is the leading cause of bacterial diarrhea in the 
United States.  Each year, estimates exceed those for salmonellosis at 2.5 million cases per year.  
They cause an estimated 17% of hospitalizations and 6% of deaths caused by all foodborne 
illnesses, including bacterial, parasitic, and viral cases (Mead et al, 1999).  Complications of 
infection include septicemia, HUS, reactive arthritis, and Guillain-Barré syndrome, which can 
lead to temporary paralysis (Walder et al., 1982; Berden et al., 1979; Rhodes and Tattersfield, 
1982).    
Because campylobacteriosis is so prevalent, antibiotic resistance becomes a major 
concern.  Sánchez et al. (1994) found a trend of increased quinolone resistance in C. jejuni 
isolates.  On the average, 0% of strains tested were resistant in 1988 and 54% in 1992.  Reina et 
al. (1994) had similar results, and reported an increase in tetracycline resistance.  Tetracycline 
resistance is plasmid-mediated (Taylor et al., 1983) and reports of resistance may depend on 
specific strain and/or geographical area.  The National Antimicrobial Resistance Monitoring 
System began surveillance on resistant Campylobacter in 1997.  They discovered that 
fluoroquinolone resistance was on the rise, and patients infected with resistant bacteria had a 
longer duration of diarrhea compared to non-resistant infections (McClellan, 2002).  Engberg et 
al. (2001) discuss emerging quinolone resistance in C. jejuni and link it to antibiotic use in the 
animal industry.   
Clostridium perfringens.  Clostridium perfringens is an anaerobic Gram-positive spore-
forming rod that is widely distributed in the environment.  It is frequently found in the intestines 
of humans and animals, and its spores persist in soils.  This species is not a strict anaerobe and 
can tolerate some exposure to oxygen (Pearson, 1976).   
The organisms are classified on their ability to produce certain types of toxins (types A, 
B, C, D, and E).  Perfringens food poisoning is caused by type A strains.  Gas gangrene strains 
are also of this type (Jay, 1996).  Foods associated with this illness are meats, meat products, 
gravy, and dried or precooked foods (CDC, 2001).  It has been found on 66% of fresh pork 
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products (NRC, 1999).  Infective dose is high (approximately 108 viable cells) (Shandera et al., 
1983).  Symptoms appear 8-12 hours after consumption and include intense abdominal cramps 
and diarrhea.  The illness runs its course usually within 24 hours (Schlossberg, 2001). 
The illness is relatively mild and the true incidence of perfringens poisoning is unknown.  
It is estimated that 250,000 cases occur annually, and is one of the most commonly reported 
foodborne illnesses.  Hospitalization and death rarely occur (Mead, 1999).  
 Ingested microbes produce enterotoxin in the intestine, and the toxin binds to intestinal 
epithelial cells.  Binding is specific and leads to damaged host cell membranes which alters 
permeability properties.  Glucose absorption is inhibited, while sodium and chloride ions are 
secreted  (McDonel, 1980).  For the farmer, decreased nutrient uptake means reduced feed 
efficiency.  Eliminating C. perfringens from the intestines would improve growth performance 
(Strauch, 1987c).  Another concern to poultry farmers is necrotic enteritis caused by type A or 
type C strains, which can lead to high mortality within a flock (Porter, 1998). 
 Antibiotic resistance increases the chance of survival and decreases elimination of the 
pathogen from the gastrointestinal tract.  Tetracycline resistance is found on a conjugative 
plasmid and expression can be induced by exposure to subinhibitory levels of the antibiotic 
(Johanesen et al., 2001).  Tetracycline and macrolide-lincosamide resistance in C. perfringens 
has been correlated to antimicrobials fed to pigs (Rood et al., 1985).   
Treatment of bacterial foodborne gastroenteritis.  Gastroenteritis is considered self-
limited and usually does not require medical attention.  However, it is recommended that a 
physician be consulted if there is fever, bloody stools, significant abdominal pain, dehydration, 
or risk factors.  Treatment may include rehydration and administration of agents to control 
diarrhea.  Treatment for specific microbes will depend on the clinical situation and/or 
identification of the pathogen.  The latter requires time for growth of the organism.  Often, 
empiric antibiotic therapy with a quinolone is prescribed before a complete diagnosis is made 
(Schlossberg, 2001).  Without confirmation of a specific microbe and its resistance patterns, 
antibiotic treatment may create complications or increase severity of disease, such as prolonged 
diarrhea or HUS. 
Risk factors for patients include age and disease state.  Populations including the elderly, 
the very young, and patients recently treated with antibiotics are more susceptible to infection.  
Their intestinal flora is altered and the risk of gastroenteritis is increased.  Populations with 
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compromised immune systems including the elderly, the very young, and people with certain 
diseases (i.e., AIDS and cancer) are more susceptible to complications (Schlossberg, 2002).  A 
list of antibiotic treatments for foodborne illnesses can be found in Table 2. 
Antibiotic use in food animals (meat and dairy) has implications for treatment of all 
bacterial infections, not just foodborne illnesses.  Approved antibiotics used to treat infections in 
food animals include ampicillin, amoxicillin, erythromycin, oleandomycin, tetracyclines, 
gentamicin, streptomycin, penicillin, lincomycin, neomycin, spectinomycin, sulfonamides, and 
fluoroquinolones.  Penicillin, ampicillin, some tetraclyclines, and oleandomycin are all approved 
for use to improve growth and feed efficiency.  Some antibiotics (erythromycin and penicillin) 
are available over the counter and do not require a prescription from a veterinarian (NRC, 1999).  
All of the above mentioned antibiotics are used to treat a variety of human illnesses 
(Schlossberg, 2001).   
Recall that resistance may develop to antibiotics in the same class.  Although tetracycline 
may not be used for growth promotion, its derivatives (chlortetracycline and oxytetracycline) are 
used, and resistance to one can infer resistance to the other (Rood et al., 1985).  The use of 
virginiamycin as a growth promoter selects for resistant Enterococcus faecium and 
staphylococci, and can confer cross-resistance to streptogramins used for human therapy (SCAN, 
1998b).  The use of tylosin and spiramycin as growth promoters can result in cross-resistance to 
erythromycin in Gram-positive and Gram-negative bacteria (SCAN, 1998a).  Avilamycin is used 
as a growth promoter in swine and poultry, and has been linked to decreased sensitivity to 
evernimomicin, which has been under development for human use.  Both compounds have the 
same mode of action (SCAN, 2000). 
 
Reducing the Development and Spread of Antibiotic Resistance 
There are several approaches to addressing the increasing problem of antibiotic resistant 
microorganisms.  Each has advantages and disadvantages.  Some proposed solutions only side 
step the true problem.  Others are more difficult to achieve, but have positive and lasting results.  
Nevertheless, steps must be taken to prevent a post-antibiotic era.  As previously discussed, 
pathogens not only become non-responsive to antibiotics, but their virulence may increase and 
severity of disease may intensify.   
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Table 2.  Antibiotic therapy for food-borne gastroenteritis.a 
Bacteria Preferred  Alternatives Comments 
Salmonella 
typhimurium 
Ciprofloxacin or 
Ceftriaxoneb 
Chloramphenicol, 
Amoxicillin or TMP-
SMXc,d 
 
Campylobacter 
jejuni 
Erythromycin Ciprofloxacin, 
Aminoglycosides, 
Chloramphenicol 
 
EIEC, ETEC, 
EPECe 
Quinolonef TMP-SMX, double 
strength 
Antibiotic therapy is 
not recommended for 
EHEC strains 
Clostridium 
perfringens 
  Antibiotic treatment not 
recommended 
aTable adapted from Scholssberg, D., ed.,  2001.  Current Therapy of Infectious Disease. 
bCeftriaxone is a third-generation cephalosporin. 
cTMP-SMX = trimethoprim-sulfamthoxazole. 
dAmoxicillin or TMP-SMX treatment for neonate or immunocompromised child only after 
patient is stable and susceptibility data is known. 
eEIEC = enterinvasive E. coli, ETEC = enterotoxogenic E. coli, EPEC = enteropathogenic E. 
coli, EHEC = enterohemorrhagic E. coli. 
fQuinolone oral therapy options include ciprofloxacin, ofloxacin, and levofloxacin. 
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Discovery and creation of new antibiotics.  A temporary solution is the discovery or 
creation of new antibiotics.  Bacteria that were once difficult to grow in the laboratory can now 
be cultivated courtesy of newer, more successful culturing methods (Kaeberlein et al, 2002).  
When newly discovered bacteria are studied, chemicals they produce are also studied.  In some 
cases, these chemicals are unique and may be antimicrobial in nature.  Well-studied bacteria or 
fungi may also produce novel antimicrobials.  A strain of the bacterium Bacillus cereus isolated 
from soil was found to produce a bacteriocin (a miniature protein) that inhibited the growth of 
pathogens and food spoilage bacteria (Bizani and Brandelli, 2002).  Plus, scientists are constantly 
creating synthetic antibiotics and finding new drug targets (Silver and Bostian, 1993). 
 One advantage to this approach is good response to treatment.  When new antibiotics are 
introduced effectiveness to treat or prevent disease in humans is very successful at first.  When 
penicillin was first introduced it was considered a miracle drug and prevented many deaths due 
to common infections (Levy, 1992).  However, microbes have the genetic ability to develop 
resistance quickly to any antimicrobial introduced.  When penicillin resistance became prevalent 
in Staphylococcus aureus, methicillin became the drug of choice to treat infections.  Only two 
years after being introduced, methicillin-resistant S. aureus (MRSA) isolates were discovered in 
the United Kingdom (Jevons, 1961).  This led to the use of vancomycin to treat MRSA 
infections, and now vancomycin-resistant S. aureus strains have emerged (Sieradzki et al., 1999; 
Smith et al., 1999).  Emerging resistance to antibiotics applies to other pathogens as well, such as 
Streptococcus pneumoniae, Enterococcus species, E. coli, and Klebsiella pneumoniae 
(Georgopapadakou, 2002). 
Altering the use of antibiotics in human therapy.  Antibiotics will always maintain a 
place in the treatment and prevention of diseases.  Notwithstanding, there are circumstances 
where non-use of antibiotics is appropriate.  Each year, millions of antibiotics are prescribed for 
colds, upper respiratory tract infections, and bronchitis (Gonzales et al., 1997).  Antibiotics are 
only effective for treating bacterial or fungal infections and have little to no effect on these 
common ailments.  Physicans’ habits and pressure from patients cause over-prescription and lead 
to misuse resulting in antibiotic resistance (Williams and Heymann, 1998).  
 In Hungary in the 1980’s, penicillin was cheap and overuse led to 50% of pneumococcus 
infections reported as penicillin resistant.  By 1992, resistant infections were down by 16%.  This 
occurred in part because physicians changed prescribing habits, relying on other classes of non-
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β-lactam antibiotics (Nowak, 1994).  This suggests that rotational use of antibiotics could 
alleviate some resistance problems. 
 Empiric antibiotic therapy is when antibiotics are administered early in an illness prior to 
culture identification and clinical response.  These antibiotics are generally broad-spectrum, 
meaning they are active against a wide range of organisms.  Conversely, narrow-spectrum drugs 
may target a specific genus or species of microbe (Conte, 2002).  If the illness is caused by an 
antibiotic resistant strain, certain empiric antibiotics might not be appropriate.  One author 
suggests that doctors use surveillance to make an educated decision on which antibiotic therapy 
to administer.  Setting up surveillance systems could provide information to support decisions 
based on level of resistance in geographical regions as well as changes in the level of resistance.  
A web-based searchable database would provide doctors quick and easy access to this 
information (Felmingham, 2002). 
 Finally, a hospital in Finland was able to eliminate 10 strains of MRSA and prevent the 
spread of nosocomial (hospital acquired) MRSA infections.  This was accomplished through 
strict and aggressive control measures.  MRSA-positive patients were treated in contact isolation, 
and staff was intensively educated on hospital hygiene (Kotilainen et al, 2003). 
Altering the use of antibiotics in livestock.  There is without question a link between 
antibiotic use in livestock and antibiotic resistant bacteria affecting humans.  Growing concerns 
were voiced by the Swann Committee in England in a 1969 report (Swann, 1969).  The World 
Health Organization (WHO, 1997) and the United States Food and Drug Administration (FDA, 
2000) have also reported possible medical risks resulting from the use of antimicrobials in 
animal feeds.  The conclusions of these reports call for the limited use and elimination of 
antibiotics as growth promoters in animal feeds.  More recently, Engberg et al. (2001) tracked 
macrolide and quinolone resistance emergence in Campylobacter species.  They concluded that 
quinolone resistance in humans frequently coincides with or follows the approval of 
fluoroquinolone (a type of quinolone) use in livestock.  
Several countries have already taken steps towards eliminating antibiotics as growth 
promoters.  The European Union (EU) includes 15 member countries and 13 other eastern and 
southern European countries preparing for accession.  The Council of the Union has passed 
several directives concerning additives in feedstuffs.  The first Council Directive was passed in 
1970 (EC, 1970).  Since then there have been numerous amendments and regulations passed into 
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law (EC, 1994).  Additives, including antibiotics, are authorized for a limited time and must be 
re-evaluated and re-authorized for continued use.  Re-authorization requires the company to 
prove efficacy and safety.  The additive must improve the feedstuffs or livestock without causing 
harm to the environment, animals, or humans.  Harm includes development of antibiotic 
resistance to a particular antibiotic used in human medicine, or the development of cross-
resistance to other antibiotics used in human medicine.  The EU has already banned avoparcin 
(EC, 1997), bacitracin zinc, spriramycin, virginiamycin, and tylosin phosphate (EC, 1998a) due 
to antibiotic resistance.  Carbadox and oliquindox were banned due to genotoxic, carcinogenic, 
and tumorigenic properties (EC, 1998b).  The remaining growth promoting antibiotics 
flavophospholipol (flavomycin), salinomycin sodium, lasalocid sodium, and monensin sodium 
are being re-evaluated (EC, 2002). 
While some antibiotic resistant genes will remain in the environment, there is evidence 
that resistance levels decrease after withdrawal of antibiotics in animal feeds. Some resistance is 
acquired through chromosomal mutation, as previously discussed.  This mutation puts a strain on 
the cell and is conditional on continued growth under antibiotic pressure.  When antibiotic 
pressure is removed, resistance may return to low levels.  This has been shown for tetracycline 
and chloramphenicol resistance in E. coli (George and Levy, 1983).  However, even with 
removal of antibiotics, low levels of resistance may remain.  Low-level resistance is a precursor 
in adaptive evolution towards high-level, clinical resistance (Baquero, 2001).  For example, a 
combination of low-level antibiotic resistance mechanisms may have a synergistic, additive 
effect resulting in high-level resistance. 
The other method of resistance is through mobile genetic elements such as plasmids, 
transposons, integrons, and phages as previously discussed.  One study has shown that exposure 
to antibiotics increases transfer rate of plasmids encoding antibiotic resistance in Bacteriodes 
species found in the human colon (Stevens et al., 1992).  By removing antibiotic pressure there is 
less of a need for microbes to develop and/or transfer antibiotic resistance genes.  Linton (1976) 
observed a decline in resistant E. coli isolated from swine feces after the removal of an antibiotic 
(aureomycin) from drinking water.  Resistance declined from 90% resistant isolates at 93 days 
prior to slaughter to 35% on the day of slaughter.  Resistance was attributed to transferable 
plasmids.  In another study, six months after the removal of tetracycline from a chicken farm, 
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there was a reversal in selection for resistant organisms in human farm residents’ fecal flora.  
Resistant bacteria contained transferable plasmids (Levy et al., 1976).   
Alternatives to antibiotics.  Animals carry bacteria in their feces and may contaminate 
carcasses, passing the organisms onto the meat products, and finally to the consumer.  Bacteria 
that develop antibiotic resistance in the animal may also follow this route.  If the resistant 
bacteria are pathogens, severe or untreatable illness may occur.  Reducing pathogens in the 
animal decreases the chance of carcass contamination and illness in humans.  However, 
antibiotic resistant bacteria may not be eliminated in animals by sub-therapeutic levels of 
antibiotics.  Carcass contamination is unavoidable, but there are alternatives to antibiotics for the 
purpose of growth promotion in livestock.  These alternatives can be used to prevent 
development and spread of antibiotic resistance as well as decrease the number of disease-
causing organisms in livestock. 
Animals that become stressed have a tendency to developed stress-related illnesses.  
Causes of stress include large numbers of animals of different origins in confined spaces, poor 
hygiene, climate conditions, and raising leaner but heavier animals.  Sub-therapeutic levels of 
antibiotics are often fed to prevent stress-related illnesses.  Reducing stress and/or replacing 
antibiotics with alternatives can eliminate the need for growth promoting antibiotics.  A German 
study concluded that a homeopathic mixture of herbs and minerals was more effective at 
preventing diseases of the respiratory tract in pigs than sub-therapeutic levels of antibiotics 
(Albrecht and Schütte, 1999). 
A probiotic is a “live microbial feed supplement which beneficially affects the host by 
improving its intestinal microbial balance” (Fuller, 1989).  Probiotics include many bacterial 
species and some fungi.  Probiotics are associated with improved performance and reduction of 
disease.  Piglets fed 106-107 viable spores of Bacillus lichenformis or Bacillus cereus var. toyoi 
exhibited reduced incidence and severity of diarrhea, significantly lowered mortality, and 
increased performance compared to negative controls (Kyriakis et al, 1999).  In another study, 
piglets with rotavirus and E. coli associated diarrhea were fed 109 cfu/piglet/day (colony forming 
units per pig per day of Bifidobacterium lactis (Shu et al., 2001).  The probiotic group exhibited 
reduced severity of diarrhea, increased performance, and lower concentrations of fecal rotavirus 
and E. coli compared to negative controls.  Probiotics may also have a direct effect on the host’s 
intestinal morphology and mucins (Baum et al., 2002). 
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A prebiotic is a “non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth and/or activity of one or a limited number of bacteria in the 
colon” (Gibson and Roberfroid, 1995).  Prebiotics include non-digestible but fermentable 
carbohydrates (oligo- and polysaccharides), some proteins, and certain lipids.  The goal is to 
stimulate growth of advantageous bacteria (bifidobacteria and lactobacilli) while suppressing 
adverse bacteria (pathogens).  In one study, rats fed resistant potato starch had stimulated growth 
of bifidobacteria (Kleessen et al., 1997).  Another study indicated that swine treated with 
fructooligosaccharides in their drinking water had reduced fecal shedding of S. typhimurium 
(Letellier et al., 2000). 
Food ingredients may be classified as a probiotic or prebiotic.  Probiotic bacteria are used 
in cheeses, yogurts, sausages, and fermented milk.  Dietary fiber is considered a prebiotic and is 
found in many foods of plant origin.  Other ingredients may also have beneficial health effects.  
Phytochemicals are biologically active plant chemicals.  For example, the anti-cancer compound 
lycopene is found in tomatoes (Love et al., 2000).  Collectively, any food or food ingredient that 
may provide a health benefit beyond the traditional nutrients it contains can be called a 
“functional food” (Thomas and Earl, 1994).  A variety of foods have anti-cancer properties, 
including soy, flaxseed, tomatoes, garlic, broccoli, tea, fish, dairy products, and beef (Hasler, 
1998).   
There are several terms used in the United States today to describe specific categories of 
foods (Table 3).  The definitions often overlap and it can be difficult to categorize some 
particular foods.  Currently, herbs are not considered foods or drugs, but “dietary supplements” 
by the Food and Drug Administration (DSHEA, 1994).  However, in other countries such as 
Germany, herbs are considered to be drugs and are strictly controlled by the government 
(Blumenthal, 1998).  In this text, functional foods and herbs will be considered separate 
categories, but collectively will be referred to as foods unless specifically noted. 
Studies of foods in livestock diets are limited.  There is some information available on 
clinical studies in humans, but studies on the effect of animal performance and gut microbiology 
are few.  In some farming districts of Australia, it is a common practice to add raspberry juice or 
raspberry cordial (35% pure fruit juice) to the drinking water of livestock and humans (Ryan et 
al., 2001).  This practice is thought to prevent or cure the symptoms of gastroenteritis.  However, 
there is little to no scientific evidence to support this claim.  Ryan et al. (2001) demonstrated the  
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Table 3.  Definitions of food terms.   
Term Definition Reference
Dietary 
Supplement 
A product (other than tobacco) that is intended to 
supplement the diet that bears or contains one or more 
of the following dietary ingredients: a vitamin, a 
mineral, an herb or other botanical, and amino acid, a 
dietary substance for use by man to supplement the 
diet by increasing the total daily intake, or 
concentrate, metabolite, constituent, extract, or 
combinations of these ingredients….is intended for 
ingestion in pill, capsule, tablet, or liquid form….is 
not represented for use as a conventional food. 
DSHEA, 1994
Food Any raw, cooked, or processed edible substance, ice, 
beverage, or ingredient used or intended for use or for 
sale in whole or in part for human consumption, or 
chewing gum. 
FDA, 1999
Functional 
food 
Any food or food ingredient that may provide a health 
benefit beyond the traditional nutrients it contains. 
Thomas and 
Earl, 1994
Herb A plant or plant part that is used to make medicine, 
food flavors (spices), or aromatic oils for soaps and 
fragrances. 
Strohecker, 
1994
Medical food A food which is formulated to be consumed or 
administered enterally under the supervision of a 
physician and which is intended for the specific 
dietary management of a disease or condition for 
which distinctive nutritional requirement on the basis 
of recognized scientific principles are established by 
medical evaluation. 
U. S. Congress, 
1988
Nutraceutical Any substance that may be considered a food or part 
of a food and provides medical or health benefits, 
including the prevention and treatment of disease. 
Love et al., 
2000
Prebiotic Non-digestible food ingredient that beneficially affects 
the host by selectively stimulating the growth and/or 
activity of one or a limited number of bacteria in the 
colon. 
Gibson and 
Roberfroid, 
1995
Probiotic Live microbial feed supplement which beneficially 
affects the host by improving its intestinal microbial 
balance. 
Fuller, 1989
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antimicrobial nature of raspberry juice and cordial, inhibiting Gram-negative and Gram-positive 
pathogens.   
Echinacea (purple coneflower) is an herb that can increase immune function (Rehman et 
al., 1999).  One study demonstrated that inclusion of 3% echinacea in swine diets resulted in 
improved feed efficiency and daily gain compared with 0 or 1.5% echinacea.  Daily gain of the 
pigs on the 3% diet was also equal to the control diet containing the growth promoter carbadox  
(Holden and McKean, 2000). 
 
Advantages and Disadvantages of Functional Foods and Herbs 
 There are advantages and disadvantages to inclusion of food into livestock diets.  Each 
must be studied before decisions are made, and the benefits must outweigh the risks.  Scientific 
research must come first, followed by education of the community, then implementation on the 
farm. 
Foods are not regulated as drugs are, and do not have to go through a lengthy approval 
process (NRC, 1999).  Implementation of foods and herbs into the diet can begin without a 
waiting period.  They can be readily available in mass quantities.  They are also considered a 
“natural” alternative, which is becoming an increasing public demand.  
Another problem is acceptance of new ideas by profit driven industries.  Pharmaceutical 
companies would lose revenue from loss of antibiotic sales.  Plus, farmers are leery of 
implementing new ideas.  Antibiotics are confirmed to improve livestock performance.  Studies 
have shown a 33 to 75% improvement in growth compared to non-antibiotic supplementation 
(Hays and Speer, 1960).  The difference in percentages was due to environment.  Cleaner 
conditions and healthier animals resulted in a smaller response to antibiotics.  Other studies 
under experimental conditions have also shown growth improvement due to antibiotic 
supplementation (Cromwell, 2001). 
A food must be proven to improve performance without side effects.  Ephedra is an herb 
considered to be a dietary supplement and is not strictly regulated by the FDA.  It is used to 
encourage weight loss or increase energy performance of athletes.  This herb has been linked to 
stroke, heart disease, and sudden death (Samenuk et al., 2002).  Garlic has been the subject of 
many studies and is thought to have multiple health benefits (Amagase et al., 2001).  Yet, when 
included in a swine diet, animals had decrease performance and extremely objectionable off-
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flavors in the meat (Holden et al., 1998).  Animal studies must be done in order to get a true 
sense of the effects on treatment and prevention of diseases, growth performance, and quality of 
the final product. 
It is more costly to raise livestock without the use of growth promoting antibiotics 
(Larson and Kliebenstein, 2002).  This does not take into account replacing antibiotics with 
alternatives.  More importantly, it does not include the human cost of antibiotic resistance and 
the ability to effectively prevent and treat disease.  Drugs of first choice are abundant and 
relatively cheap.  If the first round of therapy is ineffective, a more costly drug might be the 
alternative choice (Conte, 2002).  In extreme cases, the cost is loss of life due to an untreatable 
disease. 
Another dilemma involves standardization.  What are the active compounds in the food?  
How do they benefit the animal?  What level of the compound is required in order to see a 
beneficial result?  Are the levels consistent between cultivars?  Many factors can affect the 
chemical composition of foods.  Some herbal supplement companies impose standardization of 
active ingredients on their own products (Ternus, 1999).  
A major group of biologically active ingredients in plants is phenolic compounds 
(Shahidi and Naczk, 1995).  These phytochemicals contain at least one aromatic (benzene) ring 
with one or more hydroxyl groups (OH) attached.  Other compounds may also be attached 
(Figure 2).  Level of phenolics may change depending on environmental conditions or plant 
cultivar. 
Growing and harvesting conditions will have an affect on chemical composition.  What 
type of soil is the plant grown in, and does is contain the proper nutrients?  What are the weather 
conditions, has there been a drought, a late freeze, or ideal conditions?  Geographic location can 
dictate soil type and climate to some degree.  Crop load will affect chemical composition.  High 
yielding apple trees have been shown to have smaller, less colorful fruits.  Lower crop loads 
resulted in increased quality and higher phenolic concentrations in Jonagold Apples (Stopar et 
al., 2002).  Maturity at harvest plays a role.  Broccoli and cauliflower harvested from 3-day-old 
sprouts had higher concentrations of anticancer compounds compared to mature plants (Fahey et 
al., 1997).   
Stress can cause chemical changes in plants.  Physical stresses can occur from harvesting 
or insect infestation, and biological stresses can occur from fungal, bacterial, or viral infection.   
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Figure 2.  Benzene ring and phenolic compounds. 
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Phenolic compounds are a main defense chemical in many plants (Shahidi and Naczk, 1995).   
Stress response results in an increase in total phenolics content (Rhodes and Wooltorton, 1978). 
Food processing can cause chemical changes.  Thermally processed tomatoes into paste 
resulted in a decrease of the anti-cancer compound lycopene (Takeoka et al., 2001).  Increased 
cooking time and presence of skin increased phenolic content of peach puree without affecting 
quality (Talcott et al., 2000). 
Regardless, active ingredients must be studied in the test tube (in vitro) and in living 
systems (in vivo) to get a complete picture of how a food is functional.  Phenolic compounds are 
a very active group of phytochemicals and have been found to have antimicrobial, antioxidant, 
and anticarcinogenic activities.  Phenolics extracted from the herb Scrophularia inhibited both 
Gram-positive and Gram-negative bacteria including Bacillus subtilis, Staphylococcus aureus, E. 
coli, S. typhimurium and Moraxella lacunata (Fernández et al., 1996).  A direct relationship 
between antioxidant activity and total phenolic content of various vegetables, fruits, and herbs 
has been demonstrated (Velioglu et al., 1998).  However, composition of the phenolics was 
different depending on plant type and was a factor in level of antioxidant activity.  Antioxidant 
activity has been linked to anticarcinogenic properties due to the ability of phenolics to prevent 
DNA damage (Lodovici et al., 2001).  
 
Caffeic Acid and Chlorogenic Acid 
Some of the most common phenolic compounds found in foods of plant origin are the 
hydroxycinnamic acids (HCA), also called phenolic acids (Kroon and Williamson, 1999).  HCAs 
contain at least one cinnamic acid and at least one –OH group (Figure 3).  In particular, two 
prevalent HCAs are caffeic acid (CFA) and chlorogenic acid (CGA).   
Caffeic acid is the simplest of the HCAs, bearing only a simple cinnamic acid group and 
two -OH groups (Figure 3).  It has been found in numerous foods, including cereals, legumes, 
oilseeds, fruits, vegetables, herbs, and beverages (Table 4).  CFA is the predominant HCA in 
most fruits (Shahidi and Naczk, 1995). 
Caffeic acid has been shown to have antioxidant activities.  Oxidative damage is caused 
by free radicals.  Metal ions can initiate the formation of free radicals.  CFA is able to chelate 
(bind) iron (Fe2+) due to its hydroxyl groups (Kono et al., 1998) and has also been shown to 
chelate copper (Cu2+) and scavenge free radicals (Nardini et al., 1995).  In the latter study, CFA  
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Figure 3.  Cinnamic and hydroxycinnamic acids. 
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Table 4.  Caffeic acid and chlorogenic acid content of selected foods and beverages. 
Food/beverage Caffeic Acid Chlorogenic       Acid Reference 
Apples 85-1270 mg/kg 173 mg/kg Stich, 1991 
van der Sluis et al., 2001 
Artichoke 219 mg/kg  Radtke et al., 1998 
Barley 7.0-18 mg/kg  Hernanz et al., 2001 
Beer, German 1 mg/L  Shahidi and Nazck, 
1995 
Blueberry 977 mg/kg 1851-2075 mg/kg Radtke et al., 1998 
Schuster and Herrmann, 
1985 
Broccoli 19 mg/kg  Radtke et al., 1998 
Brussel sprouts 34 mg/kg  Stich, 1991 
Carrot, orange 85 mg/kg  Alasalvar et al., 2001 
Carrot, purple 24 mg/kg 541 mg/kg Alasalvar et al., 2001 
Cherry, sour 121 mg/kg  Radtke et al., 1998 
Coffee 631 mg/kg 1300 mg/L Radtke et al., 1998 
Stich, 1991 
Corn 4.5 mg/kg  Shahidi and Naczk, 
1995 
Echinacea purpurea 
(herb) 
125 mg/kg 320 mg/kg Głowniak et al., 1996 
Eggplant 330 mg/kg  Radtke et al., 1998 
Endive 284 mg/kg  Radtke et al., 1998 
Grapefruit 40 mg/kg  Radtke et al., 1998 
Kiwi 384 mg/kg  Radtke et al., 1998 
Lettuce 160-900 mg/kg  Stich, 1991 
Oats 1-5 mg/kg  Shahidi and Naczk, 
1995 
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Table 4 (continued)    
Peach 159 mg/kg  Radtke et al., 1998 
Pear 77 mg/kg 
 
18-141 mg/kg Raktke et al., 1998 
Amiot et al., 1995 
Plum 110 mg/kg  Raynal et al., 1989 
Potato  96-187 mg/kg Friedman, 1997 
Prune 9-10 mg/kg 411-436 mg/kg Donovan et al., 1998 
Sorghum 6.0-8.7 mg/kg free  
17-45 mg/kg bound 
 Shahidi and Naczk, 
1995 
Strawberries 15-39 mg/kg  Stich, 1991 
Sunflower, meal  0.2% 2.7% Cater et al., 1972 
Tea 250 mg/kg  Stich, 1991 
Tea, fennel  560-1000 mg/kg Bilia et al., 2000 
Tomato 24 mg/kg  Radtke et al., 1998 
Wine, red 6-13 mg/L  Frankel et al., 1995 
Wine, white 1-4 mg/L  Frankel et al., 1995 
 
 
 31
inhibited the oxidation of low-density lipoproteins (LDL), which is linked to atherosclerosis and 
heart disease. 
CFA has been the focus of several antimicrobial studies.  It has shown significant growth 
inhibition of C. perfringens without inhibiting Bifidobacter and Lactobacillus (Lee et al., 2001).  
Studies have shown inhibited growth of E. coli and K. pneumoniae at 300 ppm and the fungus 
Aspergillus at 200 ppm, and completely inhibited aflatoxin production at 200 ppm (Aziz et al., 
1998).  The inhibitory activity was attributed to presence of –OH groups.  E. coli O157:H7 and 
S. typhimurium were also inhibited by 350 ppm CFA using an agar dilution method (Tun el and 
Nergiz, 1993).  Staphylococcus aureus, Bacillus subtilis, and the yeast Candida albicans were 
inhibited at 200 ppm, while Cornybacterium diptheria, Aspergillus niger, Aspergillus flavus, and 
Pullularia pullularis were inhibited by 100 ppm of CFA (Binutu et al., 1995).  Studies vary on 
whether CFA is an effective inhibitor of Gram-negative organisms.  Regardless, phenolic content 
of some foods may affect survivability of Gram-negative pathogens.  CFA in apple juice had a 
concentration dependent affect on the survival of E. coli O157:H7 (Reinders et al., 2001).  
Antiviral activity against Vesicular Stomatitis Virus (VSV) has also been reported at the level of 
500 ppm CFA (Cheminat et al., 1988). 
Chlorogenic acid is made up of two subunits, caffeic acid and quinnic acid (Figure 3).  
These subunits are released with hydrolysis.  CGA is the most abundant soluble form of HCAs in 
the diet (Faulds and Williamson, 1999) and is thought to be the source of dietary CFA (Kroon 
and Williamson, 1999).  CGA has been found in many of the same foods as caffeic acid (Table 
4).  CGA is also an antioxidant, with the same mechanisms as CFA (Kono et al., 1998).  It has 
been shown to inhibit DNA damage due to oxidation (Kasai et al., 2000) and prevent colon 
cancer in rats (Mori et al., 2000).  One study suggests its usefulness for controlling glucose levels 
in non-insulin-dependent diabetes (Hemmerle et al., 1997).  CGA also has antimicrobial activity, 
though it is less studied than CFA.  Shigella sonnei (Group D) was 78% inhibited by 400 µM of 
CGA (approximately 145 ppm; Tsou et al., 2000).   
 
Influence of Diet on Health 
The microbial ecology of an animal’s gastrointestinal tract is a major factor in 
maintaining animal health.  The natural flora in the intestine helps animals resist infections by 
competing with pathogens (Fuller, 1989).  Volatile fatty acids (VFAs) are produced as a result of 
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microbial carbohydrate fermentation in the gut, and are absorbed and used as a source of energy 
in the large intestine of non-ruminants (Wolin, 1981).  Diet composition greatly influences the 
microbial balance (Varel et al., 1984; Varel et al., 1987), and therefore influences disease 
resistance and available energy.  Studying the effect of diet on microbial populations can be 
accomplished by studying live animals (in vivo), or environments in a test tube that mimic real 
life situations (in vitro).  Studies on whole foods may provide an overall picture.  However, in 
order to know specifically which phytochemicals have an effect, individual compounds must be 
studied separately.   
Many species of animals are used to produce meat or dairy products.  Pork consumption 
accounts for 40% of the annual total world consumption of meat (Pond and Lei, 2000).  
Improving growth characteristics are a main concern for farmers.  However, studying swine may 
have human health implications.  Despite some differences, pigs have an omnivorous digestive 
system similar to humans.  Anaerobic fermentation of fiber and VFA production are comparable, 
and pig models are often used to predict what might happen in humans (Pond and Lei, 2000).   
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CHAPTER 3 
Methods Development 
 
Introduction 
 Certain aspects of this study required preliminary work prior to the main projects.  
Particular details of established and standard methods did not work upon first or second attempts.  
This required that the methods be adjusted slightly in order to achieve repeatable results before 
conducting the main study.  The major factor was media composition.  
 
Study 1.  Aerobic Culture Growth in Ethanol    
 
Introduction 
 The minimum inhibitory concentrations (MICs) of antimicrobial compounds on the 
growth of aerobic cultures were tested using the macrobroth dilution method as previously 
described (NCCLS, 2000).  This method required that the compounds be solubilized in broth 
used to grow the bacteria.  The compounds used in this study, caffeic acid (CFA) and 
chlorogenic acid (CGA) were not water soluble.  CFA and CGA were previously reported to be 
freely soluble in alcohol (Budavari, 1989), and therefore the broth was reformulated to contain a 
specific amount of alcohol.  Ethanol is lethal to aerobic bacteria in high concentrations.  The 
objective of this preliminary study was to determine the ability of aerobic cultures to survive and 
grow in broth containing low concentrations of ethanol.   
 
Materials and Methods 
Media   
Mueller-Hinton Broth (MHB; Difco Laboratories, Detroit, MI) was mixed with distilled 
water, 10.3 mL (10 mL after autoclaving) distributed into tubes, and autoclaved for 10 min at 
121°C.   
Ethanol (95%) was cold sterilized using a sterile Swinnex-25 syringe apparatus 
(Millipore Corporation, Bedford, MA) containing an Isopore™ membrane filter with 0.2µm pore 
size (Millipore).  The volume of several MHB tubes were averaged and used as a base to 
determine the amount of filtered 95% ethanol to be aseptically added to achieve a final 
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concentration of 3% ethanol in the MHB tubes.  An aliquot (330 µL) of 95% ethanol was added 
for every 10 mL MHB.   
  
Bacterial cultures and conditions 
Cultures tested were Staphylococcus aureus ATCC 12600, S. aureus ATCC 25923, S. 
aureus ATCC 27543, S. aureus ATCC 43300, Escherichia coli ATCC 11775, E. coli ATCC 
25922, E. coli 25404, E. coli 43895, Salmonella enteritidis 108A (University of Kentucky Food 
Science stock culture), Salmonella choleraesuis subsp. choleraesuis (Smith) Weldin serotype 
Typhimurium ATCC 13311, S. choleraesuis subsp. choleraesuis (Smith) Weldin serotype 
Typhimurium ATCC 700408, and Salmonella sp. TT42 (University of Kentucky Food Science 
stock culture isolated from swine feces).    
 Frozen stock cultures were transferred twice into MHB and incubated at 35°C for 24 hr.  
Cultures were checked for purity, transferred to MHB containing 3% ethanol, and incubated in 
the same conditions.  The controls contained MHB with no ethanol.  Presence or absence of 
growth was visually observed at 24 hr and compared to controls. 
 
Results and Discussion 
 Two of the bacteria tested, S. enteritidis 108A and E. coli ATCC 25404, were inhibited 
by ethanol (growth was less than 0.125 McFarland).  None of the other cultures were affected by 
the addition of 3% ethanol, and growth was comparable to the control with no ethanol (growth 
was >0.5 McFarland).  
It is important when testing the MIC of a compound to eliminate possible interference.  
First, susceptibility cannot be reliably determined unless there is adequate growth.  Ethanol 
inhibited growth of the two bacterial cultures, and it would not be possible to determine whether 
CFA or CGA would inhibit growth.  Therefore, the two bacteria inhibited by 3% ethanol were 
removed from further MIC testing.  
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Study 2.  Compound and Agar Component Interaction 
 
Introduction 
 The MICs of antimicrobial compounds on the growth of anaerobic cultures were to be 
tested using the agar dilution method as previously described (NCCLS, 2001).  This method calls 
for the use of a supplemented blood agar for the testing of the compounds.  A previous study 
showed that Clostridium perfringens ATCC 13124 was inhibited by 0.1 mg (100 µg) of CFA 
using a disk diffusion method (Lee et. al., 2001).  Another study indicated that C. perfringens 
ATCC 3624 was inhibited by 500 ppm (500 µg/mL) of CFA using a broth dilution method 
(Debrauwer, et. al., 1989).  In this study, 1000 ppm of CFA failed to inhibit C. perfringens 
ATCC 13124 and C. perfringens 92D.   
Other studies have shown that CFA and CGA can chelate iron (Kono et. al., 1998) and 
bind to hemoglobin (Suryaprakash et. al., 2000).  The objective of this preliminary study was to 
determine which component of the supplemented blood agar was interacting with the compounds 
and interfering with the testing. 
 
Materials and Methods 
Antimicrobial compound 
A 10 mg/mL stock solution of CFA (Sigma-Aldrich, St. Louis, MO) was solubilized in 
70% ethanol and stirred with a magnetic stir bar for 5 min with gentle heating (40°C).  Ethanol 
solution was prepared using distilled water.  A final concentration of 1000 ppm was achieved by 
adding 2 mL of CFA stock solution into 18 mL of medium. 
 
Media 
Mueller-Hinton broth was mixed with distilled water, distributed into tubes, and 
autoclaved at 121°C for 10 min.  Brucella broth (BB; Difco) was mixed with distilled water, 
distributed into tubes, and autoclaved at 121°C for 15 min.  Brucella broth plus 0.16% agar was 
prepared by mixing with distilled water, supplemented with 1.6 g/L granulated agar (Difco), 
distributed into tubes, and autoclaved at 121°C for 15 min.   
Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of 
distilled water was added.  Medium was allowed to sit for 10 min at room temperature before 
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autoclaving at 121°C for 15 min.  If medium was not used within 24 hr, tubes were steamed for 
an additional 10 min and cooled just before use.   
Mueller-Hinton Agar (MHA; Difco) and Brucella Agar (BA; Difco) were mixed with 
distilled water, steamed, and autoclaved at 121°C for 15 min.   
Vitamin K1 Brucella Agar (v-BA) was prepared by the addition of 5 mg/L vitamin K1 
(Sigma-Aldrich) to BA as previously described (NCCLS, 2001).  Vitamin K1 (3-
phytylmenadione) stock solution was prepared by adding 0.2 mL to 20 mL of 95% ethanol and 
stored at 4°C for no longer than one year.  Vitamin K1 working solution was prepared by adding 
1 mL of stock solution to 9 mL of sterile distilled water, and stored at 4°C for no longer than 1 
month.  Brucella Agar was mixed with distilled water, supplemented with 1 mL/L vitamin K1 
working solution, and autoclaved at 121°C for 15 min. 
Hemin Brucella Agar (h-BA) was prepared by the addition of 1 mg/L hemin (Sigma-
Aldrich) to BA as previously described (NCCLS, 2001).  Hemin stock solution was prepared by 
dissolving 0.1 g into 2 mL of 1.0 N NaOH (Fisher Scientific, Fairlawn, NJ), the volume brought 
up to 20 mL with distilled water, and sterilized at 121°C for 15 min.  Hemin was protected from 
light by wrapping the bottle in aluminum foil and stored at 4°C for no longer than 1 month.  
Brucella Agar was mixed with distilled water, supplemented with 1 mL/L hemin stock, and 
autoclaved at 121°C for 15 min. 
Supplemented Brucella Agar (s-BA) was prepared by the addition of 5 mg/mL vitamin 
K1 and 1 mg/mL hemin.  Brucella Agar was mixed with distilled water, supplemented with 1 
mL/L vitamin K1 working solution and 1 mL/L hemin stock solution, and autoclaved at 121°C 
for 15 min. 
Supplement Brucella Blood agar (s-BBA) was prepared by the addition of 5% 
defribrinated laked sheep blood (Gibson Laboratories, Lexington, KY) to sterile s-BA as 
previously described (NCCLS, 2001).  Blood and autoclaved agar were tempered to 48°C before 
the addition of 5% blood. 
All tested agar media was distributed in 18.2 mL aliquots (to achieve 18 mL after 
autoclaving) into 50-mL polypropylene BlueMax™ Falcon® conical tubes (Becton Dickinson 
Labware, Franklin Lakes, NJ).  The media was autoclaved for 15 min at 121°C.  After cooling to 
48°C, either 2 mL of CFA stock solution plus 1 mL sterile distilled water, 2 mL CFA stock 
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solution plus 1 mL sheep blood, or 2 mL 70% ethanol plus 1 mL sterile distilled water (controls) 
were added and mixed gently.  Contents of the tube were poured into a sterile 15 x 100 mm 
round petri plate (Fisherbrand; Fisher) and allowed to solidify.  Agar plates were placed in a 
35°C incubator with lids ajar for 30 min to dry and were prepared on the day of inoculation. 
 
Bacterial cultures and conditions 
Isolates tested were S. aureus ATCC 12600, S. aureus ATCC 25923, S. aureus ATCC 
27543, S. aureus ATCC 43300, C. perfringens 92D (University of Kentucky isolate from 
poultry), C. perfringens ATCC 13124, and Campylobacter jejuni ATCC 33291. 
Staphylococcus aureus cultures were transferred twice into MHB and incubated at 35°C 
for 24 hr.  Cultures were then streaked onto MHA and incubated at 35°C for 24 hr.  Typical 
colonies were selected and suspended in MHB broth until 0.5 McFarland standard was achieved.  
Cultures were then spotted (2 µL) onto the various agars containing CFA or ethanol and 
incubated for 48 hr.  Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and s-BBA. 
All incubations for C. perfringens cultures were in Gas-Pak Anaerobic System jars with 
CO2 System Envelopes (BBL, Sparks, MD) at 35°C for 24 hr.  Cultures were transferred twice 
into CM.  Cultures were then streaked onto s-BBA and incubated.  Typical colonies were 
selected and suspended in Brucella broth until 0.5 McFarland standard was achieved.  Cultures 
were then spotted (2 µL) onto the various agars containing CFA or ethanol and incubated for 48 
hr.  Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and s-BBA. 
Incubations for C. jejuni were in a Gas Pak jar with Campylobacter System Envelopes 
(BBL) at 42°C for 48 hr.  The culture was transferred twice in BB plus 0.16% agar.  Cultures 
were then streaked onto s-BBA and incubated.  Typical colonies were selected and suspended in 
BB until 0.5 McFarland standard was achieved.  Cultures were spotted (2 µL) onto agars 
containing CFA or ethanol.  Agars tested included MHA, RCM, BA, v-BA, h-BA, s-BA, and s-
BBA. 
 
Results and Discussion 
Binutu et al. (1995) had previously found that S. aureus was inhibited by CFA using an 
agar dilution method.  In this study, S. aureus cultures were used as an aerobic control using an 
agar method.  The cultures were inhibited by 1000 ppm CFA on MHA. 
 38
A summary of results can be found in Table 5.  Caffeic acid was effective at inhibiting 
growth of both C. perfringens cultures at the level of 1000 ppm on MHA, BA, h-BA, v-BA, and 
s-BA.  Supplementation with vitamin K1 had no effect on the availability of CFA and did not 
interfere with antimicrobial action.  The addition of hemin to the agar also did not interfere with 
the antimicrobial action.  The structure of hemin contains an iron atom, which is covalently 
bound to four nitrogen atoms surrounded by four pyrrole rings linked by methene bridges (Figure 
4).  The iron in hemin is also bound to a chloride atom.  Although CFA and CGA can chelate 
iron, the iron atom in hemin is not available to interact with the compounds. However, free iron 
and hemoglobin proteins are abundant in blood and were available to bind to CFA (Nilsson et al., 
2002; Moran et al., 1994a).  This binding interfered with the ability of CFA to prevent microbial 
growth.  The use of blood in agar dilution medium formulations was discontinued in all other 
tests. 
Growth of C. perfringens was not supported on RCM containing CFA or on the control 
containing 7% ethanol.  None of the media tested supported the growth of C. jejuni.  The lack of 
growth could have been due to the high level of ethanol combined with type of media used.   
 
Study 3.  Media Combinations 
 
Introduction 
 Results from Study 2 indicated that C. perfringens and C. jejuni growth was not 
supported on certain agars.  The agars contained 7% ethanol and might have influenced growth.  
Also, Stern et. al. (1988) concluded that combinations of source and growth medium influenced 
the effect of antimicrobial compounds.  The objective of this study was to determine which 
combination of media best encouraged C. perfringens and C. jejuni growth.   
 
Materials and Methods 
Media 
Brucella Agar (BA; Difco) was mixed with distilled water and autoclaved at 121°C for 
15 min.  Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of 
distilled water was added.  Medium was allowed to sit for 10 min at room temperature before  
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Table 5.  Summary of results from Study 2a.   
Medium Isolate 1000 ppm CFA 
Ethanol 
Control 
MHA S. aureus ATCC 25923 - + 
 S. aureus ATCC 27543 - + 
 S. aureus ATCC 12600 - + 
 S. aureus ATCC 43300 - + 
 C. perfringens 92D - + 
 C. perfringens ATCC 13124 - + 
 C. jejuni ATCC 33291 - - 
RCM C. perfringens 92D - - 
 C. perfringens ATCC 13124 - - 
 C. jejuni ATCC 33291 - - 
BA C. perfringens 92D - + 
 C. perfringens ATCC 13124 - + 
 C. jejuni ATCC 33291 - - 
h-BA C. perfringens 92D - + 
 C. perfringens ATCC 13124 - + 
 C. jejuni ATCC 33291 - - 
v-BA C. perfringens 92D - + 
 C. perfringens ATCC 13124 - + 
 C. jejuni ATCC 33291 - - 
s-BA C. perfringens 92D - + 
 C. perfringens ATCC 13124 - + 
 C. jejuni ATCC 33291 - - 
s-BBA C. perfringens 92D + + 
 C. perfringens ATCC 13124 + + 
 C. jejuni ATCC 33291 - - 
aMHA = Mueller-Hinton Agar, BA = Brucella Agar, h-BA = hemin supplemented Brucella 
Agar, v-BA = vitamin K1 supplemented Brucella Agar, s-BA = hemin and vitamin K1 
supplemented Brucella Agar, s-BBA = hemin and vitamin K1 supplemented Brucella Blood 
Agar.  Agars contained either 1000 ppm caffeic acid (CFA) or 7% ethanol.  (+) indicates growth, 
(-) indicates no growth. 
 40
 
 
Figure 4.  Structure of hemin. 
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autoclaving at 121°C for 15 min.  If medium was not used within 24 hr, tubes were steamed for 
an additional 10 min and cooled just before use. 
Reinforced Clostridial Medium (RCM; Difco) was mixed with distilled water, 
supplemented with 15 g/L granulated agar, and autoclaved at 121°C for 15 min.  A final 
concentration of 1.5% agar was achieved in the medium.   
Figures 5 and 6 illustrate the different combinations tested.  Agar plates containing 3.5% 
ethanol were prepared by the addition of 1 mL of 70% ethanol to tubes containing 19 mL sterile, 
tempered (48°C) agar.  Agar plates containing 7% ethanol were prepared by the addition of 2 mL 
of 70% ethanol to tubes containing 18 mL sterile, tempered agar.  Plates were dried and as 
previously described.   
 
Bacterial cultures and conditions 
All incubations for C. perfringens were incubated in anaerobic Gas-Pak jars at 35°C for 
24 hr unless otherwise stated.  Initially, C. perfringens ATCC 13124 and C. perfringens 92G 
were streaked onto s-BBA, BA, and RCM containing no ethanol and growth was observed after 
48 hr.  Stock cultures were transferred twice into CM and incubated.  Cultures were then 
streaked onto the appropriate agar.  After incubation, typical colonies were selected and 
suspended in BB until 0.5 McFarland standard was achieved.  Cultures were then spotted (2 µL) 
onto the various agars containing ethanol and incubated for 48 hr. 
All incubations for C. jejuni were in a microaeophilic incubator (5% O2, 10% CO2) for 48 
hr at 42°C.  Initially, C. jejuni ATCC 33291 was streaked onto s-BBA, BA, and MHA containing 
no ethanol and growth was observed after incubation.  The stock culture was transferred twice in 
BB plus 0.16% agar and incubated.  The culture was then streaked onto the appropriate agar.  
After incubation, typical colonies were selected and suspended in BB until 0.5 McFarland 
standard was achieved.  Cultures were then spotted (2 µL) to achieve a final inoculum of 2 x 105 
bacteria onto the various agars containing ethanol and incubated. 
 
Results and Discussion 
 A summary of results can be found in Table 6.  Clostridium perfringens growth was 
supported on s-BBA, BA, and RCM containing no ethanol.  Growth was inhibited on all agars 
containing 7% ethanol.  Most of the agars containing 3.5% ethanol only supported the growth of  
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Figure 5.  Flow chart of Clostridium perfringens for Study 3.  s-BBA = supplemented 
Brucella Blood Agar, BA = Brucella Agar, RCM = Reinforced Clostridial Medium plus 1.5% 
agar, EtOH = ethanol,  % EtOH represents total amount of ethanol in 20 mL agar plate.  
Incubations for transfers and initial agars were anaerobic at 35°C for 24 hours.  Incubations for 
plates with ethanol were 48 hours. 
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Figure 6.  Flow chart of Campylobacter jejuni in Study 3.  s-BBA = supplemented Brucella 
Blood Agar, BA = Brucella Agar, MHA = Mueller-Hinton Agar, EtOH = ethanol,  % EtOH 
represents total amount of ethanol in 20 mL agar plate.  All incubations were in a 
microaerophilic incubator (5% O2, 10% CO2) at 42°C for 48 hours. 
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Table 6.  Summary of results for Clostridium perfringens cultures from Study 3a.   
Source Agar Growth Agar Isolate Growth 
s-BBA BA + 3.5% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D + 
 BA + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
 RCM + 3.5% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D + 
 RCM + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
BA BA + 3.5% EtOH C. perfringens ATCC 13124 + 
  C. perfringens 92D + 
 BA + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
 RCM + 3.5% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D + 
 RCM + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
RCM BA + 3.5% EtOH C. perfringens ATCC 13124 + 
  C. perfringens 92D + 
 BA + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
 RCM + 3.5% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D + 
 RCM + 7% EtOH C. perfringens ATCC 13124 - 
  C. perfringens 92D - 
as-BBA = supplemented Brucella Blood Agar, BA = Brucella Agar, RCM = Reinforced 
Clostridial Medium plus 1.5% agar, EtOH = ethanol.  (+) indicates growth, (-) indicates no 
growth. 
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C. perfringens ATCC 13124, but did not support the growth of C. perfringens 92D.  Only two 
combinations, BA from BA and BA from RCM, were able to support the growth of both 
cultures.   
 The NCCLS (2001) standard for testing MICs with anaerobic cultures using the agar 
dilution method requires 2 mL of the selected compound be added to each agar plate.  Recall that 
the compounds used in this project are solubilized with 70% ethanol.  This results in 7% ethanol 
in the final agar.  Because this will not support culture growth, a lower concentration for further 
MIC testing was used.  A volume of 1 mL of the compound results in 3.5% ethanol in the final 
agar.  This concentration supported the growth of C. perfringens cultures and therefore the 
standard method was adjusted.  Brucella Agar from RCM containing 3.5% ethanol was used for 
further MIC testing for C. perfringens cultures. 
 Campylobacter jejuni growth was supported on s-BBA, BA, and MHA containing no 
ethanol.  However, growth on MHA was minimal, and it was difficult achieving 0.5 McFarland 
needed for inoculation.  There was no growth on any of the agars containing 3.5% or 7% ethanol.  
These percentages were too high to support growth.  
 
Study 4.  Ethanol and Campylobacter jejuni Growth 
 
Introduction 
 Results from Study 3 revealed that C. jejuni cultures did not grow on any of the agar 
plates tested.  This was attributed to amount of ethanol in the agar.  The objective of this study 
was to determine what ethanol concentrations would allow the growth of C. jejuni. 
 
Materials and Methods 
Antimicrobial compounds 
In order to achieve no more than 1.5% ethanol in the final media, a limit of 30% ethanol 
was set for solubility of the compounds.  Caffeic acid stock solutions of 64 and 48 mg were 
mixed in 3 mL of distilled water.  Seventy percent ethanol was added by 0.5 mL aliquots until 
the set limit was reached.  Stock solutions were stirred with a magnetic stir bar for 5 min with 
gentle heating (40°C).  Final concentrations of 640 and 480 ppm were achieved by adding 1 mL 
of CFA stock solution into 19 mL of medium.   
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Chlorogenic acid stock solutions of 64 and 48 mg were mixed with 3 mL distilled water.  
Ninety-five percent ethanol was added in 0.5 mL aliquots until CGA was solubilized.  In 
addition, a CGA stock solution of 80 mg/mL was mixed with 4 mL of distilled water.  Seventy 
percent ethanol was added by 0.5 mL aliquots until CGA was solubilized.  Stock solutions were 
stirred with a magnetic stir bar for 5 min with gentle heating.  Final concentrations of 800 and 
600 ppm were achieved by adding 1 mL of CGA stock solution into 19 mL of medium.  
 
Media 
Brucella Agar was mixed with distilled water and distributed in 19.2 mL aliquots (to 
achieve 19 mL after autoclaving) into 50-mL polypropylene BlueMax™ Falcon® conical tubes.  
The media was autoclaved for 15 min at 121°C.  After cooling to 48°C, 1 mL of  CFA stock 
solution, 1 mL of CGA stock solution, or 1 mL of 30% ethanol (controls) was added and mixed 
gently.  Contents of the tube were poured into a sterile 15 x 100 mm round petri plate and 
allowed to solidify.  Agar plates were placed in a 35°C incubator with lids ajar for 30 min to dry 
and were prepared on the day of inoculation.  
 
Bacterial culture and conditions 
Campylobacter jejuni ATCC 33291 was incubated in a microaerophilic incubator (5%O2, 
10% CO2) at 42°C for 48 hr.  Stock culture was transferred twice in BB plus 0.16% agar and 
incubated.  The culture was then streaked onto s-BBA.  After incubation, typical colonies were 
selected and suspended in BB until 0.5 McFarland standard was achieved.  The culture was then 
spotted (2 µL) onto BA containing 1 mL of the stock solution, 1 mL of 30% ethanol, or 1 mL 
sterile distilled water as previously described and incubated. 
 
Results and Discussion 
Campylobacter jejuni growth was supported agar plates containing 1.5% ethanol and was 
comparable to growth on agar plates with no ethanol.  Agar dilution plates containing 1.5% 
ethanol will be used for future MIC testing. 
Chlorogenic acid went into solution at a concentration of 16 mg/mL in 14% ethanol.  A 
volume of 1 mL was added to an agar plate for a final concentration of 800 ppm CGA and 0.7% 
ethanol.  Growth was not inhibited. 
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Chlorogenic acid also went into solution at 16 and 12 mg/mL in 23% ethanol.  A volume 
of 1 mL was added to agar plates for final concentrations of 800 and 600 ppm with 1.15% total 
ethanol.  Growth was not inhibited.   
Caffeic acid was not soluble at 12.8 and 9.6 mg/mL in 28% ethanol.  A volume of 1 mL 
was added to agar plates for a final concentration of 640 and 480 ppm with 1.4% total ethanol.  
Despite the visible insolubility, CFA inhibited growth at 480 ppm.   
The difference in the solubility of CFA and CGA lies in their structures (Figures 7 and 8).  
Chlorogenic acid includes a quinnic acid moiety and is more hydrophilic than CFA.  This 
accounts for the ability of CGA to go into solution at a much lower ethanol percentage.  
Therefore, when conducting MICs, the solubility of CFA combined with the inability of C. jejuni 
to survive on agar containing ethanol are limiting factors.   
 
Study 5.  Compound Solubility 
 
Introduction 
 There were two limiting factors for MIC testing of CFA on C. jejuni using the agar 
dilution method.  First, C. jejuni did not grow on agar dilution medium containing more than 
1.5% ethanol.  Second, CFA was not soluble in some in ethanol/water mixtures.  The highest 
concentration used for MIC testing was 1000 ppm.  In order to achieve a maximum of 1.5% 
ethanol and 1000 ppm CFA in the agar dilution medium, the following combinations for CFA 
stock solutions would be required: 
1) For 2 mL of stock solution into 18 mL agar, 10 mg/mL CFA in 15% ethanol 
2) For 1 mL of stock solution into 19 mL agar, 20 mg/mL CFA in 30% ethanol 
3) For 0.5 mL of stock solution into 19.5 mL agar, 40 mg/mL CFA in 60% ethanol 
However, Study 4 demonstrated that 9.6 and 12.8 mg/mL CFA were not soluble in 28% ethanol.  
This excluded options 1 and 2 for the stock solution.  Therefore, the objective of this study was 
to determine if 40 mg/mL CFA would solubilize in 60% ethanol. 
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Figure 7.  Structure of caffeic acid (3,4-dihydroxycinnamic acid). 
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Figure 8.  Structure of chlorogenic acid (5-caffeoylquinic acid). 
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Materials and Methods 
 Ethanol/water mixture was prepared with distilled water to achieve a 60% ethanol 
solution.  Caffeic acid stock solution was prepared by the addition of 40 mg/mL CFA to 60% 
ethanol.  The stock solution was stirred using a magnetic stir bar for 10 min with gentle heating. 
 
Results and Discussion 
Caffeic acid was soluble at the concentration of 40 mg/mL in 60% ethanol.  Therefore, 
concentrations of less than 40 mg/mL CFA will also solubilize in 60% ethanol.  This meets the 
requirements of 1.5% ethanol and 1000 ppm solubilized CFA or less in agar dilution medium.  In 
this study, it was determined that distribution of 0.5 mL stock solution (60% ethanol) into 19.5 
mL agar dilution medium was optimal for MIC testing of CFA on C. jejuni.   
 
Study 6.  In Vitro Survival of Campylobacter jejuni 
 
Introduction 
 Initially, a main objective was set to determine the effect of CFA and CGA on survival of 
C. jejuni for an in vitro study using swine feces.  However, the inoculated culture did not survive 
the incubation period.  Because a minimal medium was used, it was thought that the culture 
could not survive in that particular medium.  Thus, the objective of this study was to determine if 
C. jejuni cultures would survive the incubation period in a minimal medium. 
 
Materials and Methods 
Media 
Phosphate and magnesium chloride dilution water was prepared as previously described 
(Marshall, 1992).  Stock phosphate solution was prepared by dissolving 34 g KH2PO4 (Fischer) 
in 500 mL distilled water, pH adjusted to 7.2 with 1 N NaOH, the volume brought up to 1 L with 
distilled water, and sterilized at 121°C for 15 min.  Stock MgCl2 solution was prepared  by 
dissolving 38 g MgCl2 (Sigma-Aldrich) in 1 L distilled water, and autoclaved at 121°C for 15 
min.  Stock solutions were stored at 4°C until use.  Class C dilution water was prepared by the 
addition of 1.25 mL stock phosphate solution and 5 mL MgCl2 solution, and the volume brought 
up with distilled water to 1 L.  The pH was adjusted to 7.4 (pH 7.2 after autoclaving).  Media 
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was dispensed in aliquots of 10.2 mL into tubes or 105 mL into bottles (to achieve 9.9 and 99 
mL blanks after autoclaving, respectively).  Dilution blanks were then autoclaved for 15 or 30 
min at 121°C for tubes or bottles, respectively.  Brucella stearothermophilus spores, BT Sure 
biological indicator for steam sterilization (Barnstead/Thermolyne, Inc., Dubuque, IA), was used 
as an indicator of sterility.  Spores were autoclaved with the media then incubated at 55°C for 24 
hrs.  Lack of growth indicated the autoclave was working properly. 
Anaerobic dilution solution was prepared according to methods previously described 
(Holdeman and Moore, 1975).  The salts solution contained 0.2 g/L anhydrous CaCl2 (J. T. Baker 
Chemical Company, Phillipsburg, NJ), 0.2 g/L MgSO4•7H2O (Sigma-Aldrich), 1 g/L K2HPO4 
(Fischer), 1 g/L KH2PO4, 10 g/L NaHCO3 (Fisher), and 2 g/L NaCl (Fischer).  Salts were 
dissolved in distilled water.  For each liter of media, 500 mL of distilled water was combined 
with 2 g/L gelatin (Difco), 1 mL resazurin solution, and 500 mL of salt solution.  Resazurin 
(Sigma-Aldrich) solution was prepared by dissolving 100 mg in 100 mL distilled water.  The 
medium was boiled then cooled, and 5 g/L L-cysteine (Sigma-Aldrich) was added under a 
constant flow of CO2 using gas jets.  Medium continued under a flow of CO2 until it turned from 
pink to colorless.  A volume of 50 mL was anaerobically transferred into a 125-mL serum bottle 
under a flow of CO2.  The bottle was sealed by a butyl rubber stopper and crimp-sealed.  The rest 
of the medium was transferred to the anaerobic chamber for fecal processing.  The anaerobic 
chamber was under a CO2 environment in the absence of O2. 
Campylobacter Agar Base (Karmali; Oxoid, Hampshire, England) was mixed with 
distilled water and sterilized at 121°C for 15 min.  Sterile agar was tempered to 48°C and 
supplemented with freeze-dried Campylobacter Selective Supplement SR167E (Karmali; 
Oxoid).  One vial of supplement contained 50 mg sodium pyruvate, 16 mg cefoperazone, 10 mg 
vancomycin, and 50 mg cyclohexamide.  Vial components were dissolved by 2 mL of 50% 
ethanol and aseptically added to every 500 mL of sterile Karmali Agar.  Karmali agar was used 
for the enumeration of Campylobacter coli and C. jejuni at 42°C. 
 
Fecal samples 
Swine feces were collected from a Duroc X Landrace/Yorkshire crossbred barrow.  The 
animal was 4 months of age, weighed 60 kg, and was housed at the University of Kentucky 
Animal Laboratory.  The diet consisted of 82% corn, 16% dehulled soybean meal, 1% dicalcium 
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phosphate, and less than 1% of lysine, limestone, salt, vitamin and mineral mix, and 0.05% 
Tylan-40.  Pigs were kept in individual 5’ x 10’ pens with slatted floors, continuous lighting, and 
a constant temperature of approximately 25°C.  Water was available ad libitum.  A fresh stool 
sample was obtained, placed in a plastic bag, and delivered into the anaerobic chamber within 10 
min of collection for processing.  Anaerobic chamber was under a CO2 environment in the 
absence of O2. 
Fresh feces (10 g) was blended with 100 mL anaerobic dilution solution in a Waring 
blender for 60 seconds to achieve a 10% (w/v) fecal slurry.  The slurry (50 mL) was transferred 
into a 125-mL serum bottle under a constant flow of CO2.  The bottle was sealed by a butyl 
rubber stopper and crimp-sealed. 
 
Bacterial culture and conditions 
Campylobacter jejuni ATCC 33291 was transferred twice in BB plus 0.16% agar and 
incubated microaerophilically at 42°C for 48 hr.  The culture was streaked onto s-BBA and 
incubated for another 48 hr in the same conditions.  Colonies were suspended in sterile dilution 
water until 0.5 McFarland Standard was achieved.  An inoculum amount of 1 mL was 
anaerobically transferred to serum bottles containing anaerobic dilution solution or fecal slurry.  
Serum bottles were incubated in a shaking water bath at 125 rpm for 24 hr at 39°C.  Initial slurry 
and final samples were diluted using sterile dilution water, and 0.1 mL was plated using the 
spread plate method onto Karmali agar.  Plates were incubated in a microaerophilic incubator 
(5% O2 and 10% CO2) at 42°C for 48 hr.   
 
Results and Discussion 
A summary of results can be found in Table 7.  Bacterial counts for the initial slurry and 
slurry at 24 hr were comprised of both C. jejuni and Campylobacter coli.  Karmali agar supports 
the growth of both organisms for these incubation conditions.  Without further testing, it is not 
possible to distinguish between these two species. 
 Bacterial counts for the medium containing only the C. jejuni inoculum after 24 hr had 
good survival.  The counts were reduced by only 10% (less than 101 CFU/mL).  On the other 
hand, when feces were added to the combination, survival was drastically reduced.  The counts 
were diminished by 64% (104 CFU/mL).  The pH did not drop after 24 hr, and a pH of 6.5 is well  
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Table 7.  In vitro survival of Campylobacter jejuni in mediuma with and without feces.   
 CFU/mLc pH 
Initial fecal slurryb 1.7 x 105  
Medium plus inoculumd  
at 24 hours 
4.5 x 105 6.5 
Fecal slurry plus inoculumd 
at 24 hours 
2 x 102 6.5 
aMedium consisted of anaerobic dilution solution. 
bFecal slurry was 10% (w/v) feces (wet weight) in the medium. 
cCFU/mL = colony forming units per milliliter. 
dInoculum was C. jejuni ATCC 33291 at the level of 2 x 106 bacteria/mL. 
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within the range for supporting Campylobacter survival (optimum pH of 7.0).  Campylobacter 
requires 5-10% oxygen; yet, they can survive, but not grow, under reduced-oxygen conditions 
(BAM, 2001).  However, the microbial population of swine feces is very diverse and 
competitive.  This particular environment may introduce too much competition for C. coli and C. 
jejuni to survive and grow.   
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CHAPTER 4 
Minimum Inhibitory Concentrations of  
Caffeic Acid and Chlorogenic Acid and Their Effect on  
the Microbial Ecology of Swine Feces In Vitro 
 
Introduction 
 Preliminary work in Chapter 3 described adjustments to established and standard 
methods needed to complete this study.  These adjustments involved formulation changes to the 
different media types.   
 The first objective of this study was to determine the Minimum Inhibitory Concentrations 
(MICs) of caffeic acid and chlorogenic acid against potential pathogens.  The MIC is the 
minimal concentration of an antimicrobial required to inhibit or kill a microorganism (Murray, 
1995).  This information is useful when studying specific compounds and specific 
microorganisms.  It may also provide clues as to how an antimicrobial will affect overall 
microbial ecology. 
 The second objective was to determine the effect of caffeic acid and chlorogenic acid on 
the fecal microbial population of swine.  In vitro studies can offer a general look at the microbial 
population without the use of live animals.  In vitro studies sustain a more controlled and 
uniform environment compared to using a number of different animals.  While this provides 
invaluable information, all aspects must be considered.   
 
Materials and Methods 
Minimum Inhibitory Concentration 
Antimicrobial compounds.  Caffeic acid (CFA; Sigma-Aldrich, St. Louis, MO) and 
chlorogenic acid (CGA; Sigma-Aldrich) were tested at the levels of 0, 50, 100, 200, 300, 400, 
500, 600, 800, and 1000 ppm.  CFA and CGA were solubilized in 70% ethanol and stirred with a 
magnetic stir bar for 5 min with gentle heating (40°C).  A stock solution of 20 mg/mL was 
prepared and a portion was diluted with 70 % ethanol by a 1:2 ratio to achieve a solution of 10 
mg/mL.  A stock solution of 16 mg/mL was prepared and a portion was diluted with 70% ethanol 
in a series of 1:2 ratios to achieve concentrations of 8 mg/mL, 4 mg/mL and 2 mg/mL.  Finally, a 
 56
stock solution of 12 mg/mL was prepared and a portion was diluted with 70% ethanol by a 1:2 
ratio to achieve 6 mg/mL solution.  For the testing of Campylobacter jejuni, CFA and CGA were 
solubilized and diluted in 60% ethanol.  Ethanol solutions were prepared using distilled water.   
For aerobic cultures,  stock solutions were filter sterilized using a sterile Swinnex-25 
syringe apparatus (Millipore Corporation, Bedford, MA) containing an Isopore™ membrane 
filter with 0.2µm pore size (Millipore).   
Media.  Brain Heart Infusion Broth (BHI; Difco Laboratories, Detroit, MI) was mixed 
with distilled water, 6 mL distributed into tubes, and autoclaved for 15 min at 121°C.  Brucella 
broth (BB; Difco) was mixed with distilled water, 10 mL were distributed into tubes, and 
autoclaved at 121°C for 15 min.  Brucella broth plus 0.16% agar was prepared by the addition of 
1.6 g/L granulated agar (Difco), mixed with distilled water, 10 mL distributed into tubes, and 
autoclaved for 15 min at 121°C.  Reinforced Clostridial Medium (RCM; Difco) plus 1.5% agar 
was prepared by the addition of 15 g/L granulated agar and mixed with distilled water before 
autoclaving at 121°C for 15 min.  
Cooked Meat Medium (CM; Difco) was distributed (1.25 g) into tubes and 10 mL of 
distilled water added.  Medium sat for 10 min at room temperature prior to  autoclaving at 121°C 
for 15 min.  If the medium was not used within 24 hr, tubes were steamed for an additional 10 
min and cooled just before use.   
Mueller-Hinton Broth (MHB, Difco) was mixed with distilled water.  For culture growth 
tubes, 10 mL were distributed into tubes and autoclaved for 10 min at 121°C.   For the 
macrobroth dilution tubes used for the testing of Minimum Inhibitory Concentrations (MICs) of 
aerobic cultures, 200 mL MHB were distributed into bottles and autoclaved for 10 min at 121°C.  
Then, 0.9 mL of sterile medium was aseptically transferred to sterile 13 x 100 glass tubes in 
order to avoid inconsistent volumes from autoclaving.  The tubes were incubated at 25°C 
overnight to verify sterility.  The CFA and CGA stock solutions were prepared, as described, and 
0.1 mL was aseptically added to each sterile 13 x 100 broth tube on the day of inoculation. 
Agar dilution plates for testing the Minimum Inhibitory Concentration (MIC) on 
Clostridium perfringens cultures contained Brucella Agar (BA; Difco).  The medium was mixed 
with distilled water and distributed in 19.2 mL aliquots (to achieve 19 mL after autoclaving) into 
50-mL polypropylene BlueMax™ Falcon® conical tubes (Becton Dickinson Labware, Franklin 
Lakes, NJ).  The medium was autoclaved for 15 min at 121°C, cooled to 48°C, and 1 mL of CFA 
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or CGA stock solution was added and mixed gently.  Contents of the tube were poured into a 
sterile 15 x 100 mm sterile round petri plate (Fisherbrand, Fischer Scientific, Fairlawn, NJ) and 
allowed to solidify.  Agar plates were placed in a 35°C incubator with lids ajar for 30 min to dry 
and were prepared on the day of inoculation. 
Agar dilution plates for the MIC of Campylobacter jejuni contained Supplemented 
Brucella Agar (s-BA).  The medium was prepared by the addition of 1 mg/L hemin and 5 mg/L 
vitamin K1 to BA as previously described (NCCLS, 2001).  Hemin (Sigma-Aldrich) stock 
solution was prepared by dissolving 0.1 g into 2 mL of 1.0 N NaOH (Fisher), the volume brought 
up to 20 mL with distilled water, and sterilized at 121°C for 15 min.  Hemin was protected from 
light by wrapping aluminum foil around a dark glass bottle and stored at 4°C for no longer than 1 
month.  Vitamin K1 (3-phytylmenadione; Sigma-Aldrich) stock solution was prepared by adding 
0.2 mL to 20 mL of 95% ethanol and stored at 4°C for no longer than one year.  Vitamin K1 
working solution was prepared by adding 1 mL of stock solution to 9 mL of sterile distilled 
water, and stored at 4°C for no longer than 1 month.  Brucella Agar was supplemented with 1 
mL/L hemin stock and 1 mL/L vitamin K1 working solution.  Supplemented Brucella Agar was 
distributed in 19.8 mL aliquots (to achieve 19.5 mL after autoclaving) into 50-mL polypropylene 
BlueMax™ Falcon® conical tubes and autoclaved.  Agar was cooled to 48°C and 0.5 mL of 
CFA or CGA stock solution was added and mixed gently.  Contents of the tube were poured into 
a 15 x 100 mm sterile round petri plate and allowed to solidify.  Agar plates were placed in a 
35°C incubator with lids ajar for 30 min to dry and were prepared on the day of inoculation. 
 Supplement Brucella Blood agar (s-BBA) was prepared by the addition of 5% 
defribrinated laked sheep blood (Gibson Laboratories, Lexington, KY) to sterile s-BA as 
previously described (NCCLS, 2001).  After autoclaving, blood and agar were tempered to 48°C 
prior to addition of 5% blood.  Plates were allowed to solidify and dried for 30 min at 35°C in an 
incubator with lids ajar.  Unused plates were stored at 4°C for no longer than 48 hr.  Blood was 
stored at 4°C for no longer than 1 month. 
Bacterial Cultures and Conditions.  A complete list of bacterial strains tested is 
presented in Table 8.  Aerobic cultures, including Salmonella, Escherichia coli, and 
Staphylococcus aureus were tested for susceptibility using the macrobroth dilution method as 
previously described (NCCLS, 2000).  Frozen stock cultures were transferred into Brain Heart  
 58
Table 8.  List of bacterial strains used for Minimum Inhibitory Concentration testing. 
Strain Source Incubation conditions 
Campylobacter jejuni subsp. 
jejuni ATCCa 33291 
Human feces Microaerophilicb, 42°C, 48 
hrs 
Clostridium perfringens 
ATCC 13124 
Quality control strain, 
produces α-toxin 
Anaerobic, 35°C, 24 hrs 
Clostridium perfringens 
(92D) 
University of Kentucky 
isolate from poultry 
Anaerobic, 35°C, 24 hrs 
Escherichia coli 
 ATCC 11775 
Urine Aerobic, 35°C, 24 hrs 
Escherichia coli  
ATCC 25922 
Clinical isolate Aerobic, 35°C, 24 hrs 
Escherichia coli O157:H7 
ATCC 43895 
Hamburger Aerobic, 35°C, 24 hrs 
Salmonella choleraesuis 
subsp. choleraesuis (Smith) 
Weldin serotype 
Typhimurium  
ATCC 13311 
Food Poisoning in Man Aerobic, 35°C, 24 hrs 
Salmonella choleraesuis 
subsp. choleraesuis (Smith) 
Weldin serotype 
Typhimurium,  
ATCC 700408 
Phage type DT104, 
multi-drug resistant 
Aerobic, 35°C, 24 hrs 
Salmonella sp. (TT42) 
 
University of Kentucky 
isolate from swine feces 
Aerobic, 35°C, 24 hrs 
Staphylococcus aureus 
ATCC 12600 
Pleural fluid 
 
Aerobic, 35°C, 24 hrs 
Staphylococcus aureus 
ATCC 25923 
Clinical isolate Aerobic, 35°C, 24 hrs 
Staphylococcus aureus 
ATCC 27543 
Mastitic cow Aerobic, 35°C, 24 hrs 
Staphylococcus aureus 
ATCC 43300 
Clinical isolate, 
methicillin resistant 
Aerobic, 35°C, 24 hrs 
a ATCC = American Type Culture Collection. 
bMicroaerophilic conditions were 5% O2, 10% CO2, 85% N2. 
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Infusion broth (BHI, Difco) and incubated 24 hr at 35°C.  Cultures were checked for purity, 
transferred to fresh BHI broth, and incubated 8 hr.  Cultures were transferred into MHB 
containing 3% ethanol, and incubated for 24 hr at 35°C.  After incubation, cultures were 
transferred to MHB and adjusted to 0.5 McFarland standard.  One mL of culture was then 
transferred into macrobroth dilution tubes containing MHB and CFA or CGA, and incubated 24 
hr at 35°C.   
Clostridium perfringens cultures were tested using the agar dilution method for 
susceptibility of anaerobic bacteria according to NCCLS standards (NCCLS, 2001).  All 
incubations were in anaerobic Gas-Pak jars (BBL, Sparks, MD) using CO2 system envelopes 
(BBL) for 24 hr at 35°C.  Frozen stock cultures were transferred twice in CM.  The cultures were 
then streaked onto RCM containing 1.5% agar.  After incubation, typical colonies were selected 
and suspended in BB until 0.5 McFarland standard was achieved.  Cultures were then spotted (2 
µL) onto BA containing various concentrations of CFA and CGA stock solutions and incubated 
for 48 hr.  Hemin, vitamin K1, and blood were not added to the agar dilution plates used for 
susceptibility testing.   
Campylobacter jejuni was tested using the agar dilution method for susceptibility of 
anaerobic bacteria according to NCCLS standards (NCCLS, 2001).  All incubations were in a 
microaerophilic incubator (5% O2, 10% CO2) at 42°C for 48 hr.  Frozen stock was transferred 
twice into in BB plus 0.16% agar, and then streaked onto s-BBA.  Typical colonies were selected 
and suspended in BB until 0.5 McFarland standard was achieved.  Cultures were spotted (2 µL) 
onto s-BA containing various concentrations of CFA and CGA stock solutions and incubated.  
Blood was not added to the agar dilution plates used for susceptibility testing. 
 
In Vitro Incubation 
Media.  A complete list of media used is in Table 9.  Anaerobic dilution solution was 
prepared according to methods previously described (Holdeman and Moore, 1975).  The salts 
solution contained 0.2 g/L anhydrous CaCl2 (J. T. Baker Chemical Company, Phillipsburg, NJ), 
0.2 g/L MgSO4•7H2O (Sigma-Aldrich), 1 g/L K2HPO4, 1 g/L KH2PO4, 10 g/L NaHCO3, and 2 
g/L NaCl (Fisher Scientific).  Salts were dissolved in distilled water.  For each liter of media, 500 
mL of distilled water was combined with 2 g/L gelatin (Difco), 1 mL resazurin solution, and 500  
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Table 9.  Complete list of media and their use in this study. 
Media Purpose Target Culture and Incubation Conditions 
   
Anaerobic Dilution Solutiona In vitro incubation Fecal microflora, shaking 
water bath, 125 rpm, 39°C 
for 24 hrs 
BS-LVb Enumeration Bifidobacteria, anaerobic, 
37°C for 72 hrs 
Brain Heart Infusion broth 
(BHI)c 
Enrichment S. aureus, E. coli, S. 
enteritidis, S. typhimurium, 
Salmonella sp., 35°C for 8 
or 24 hrs 
Brucella Agar (BA)c Agar dilution susceptibility 
testing 
C. perfringens, anaerobic, 
35°C for 48 hrs.   
Brucella Broth (BB)c 0.5 McFarland standard for 
agar dilution testing 
C. perfringens, C. jejuni, no 
incubation 
Coliform/E. coli Petrifilmd Enumeration/ 
Differentiation 
E. coli, coliforms, 35°C for 
24 hrs 
Cooked Meat Mediumc Enrichment C. perfringens, anaerobic, 
35-37°C, 24 hrs 
Granulated Agarc Supplement to RCM and 
Brucella Broth 
C. perfringens, Total 
Anaerobes, C. jejuni 
Karmali Agar (KA)e Enumeration C. jejuni and C. coli, 
microaerophilic, 42°C for 
72 hrs 
Mueller-Hinton Broth 
(MHB)c 
Enrichment, 0.5 McFarland 
standard for macrobroth 
dilution testing 
S. aureus, E. coli, S. 
enteritidis, S. typhimurium, 
Salmonella sp., 35°C for 24 
hrs 
OPSPe Enumeration C. perfringens, anaerobic, 
37°C for 72 hrs 
Phosphate and Magnesium 
Chloride Dilution Waterf 
Dilution blanks All, no incubation 
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Table 9 (continued)   
Reinforced Clostridial 
Mediumc with 1.5% agar 
(RCM) 
Enrichment C. perfringens, anaerobic, 
35-37°C for 24 hrs 
Reinforced Clostridial 
Medium with 1.5% agar 
Enumeration Total Anaerobic count, 
anaerobic, 37°C for 72 hrs 
Rogosa SL Agarc Enumeration Lactobacilli, anaerobic, 37° 
for 72 hrs 
Supplemented Brucella Agar 
(s-BA)c, g 
Agar dilution susceptibility 
testing 
C. jejuni, microaerophilic, 
42°C for 48 hrs 
Supplemented Brucella 
Blood Agar (s-BBA)c, g 
Enrichment C. jejuni, microaerophilic, 
42°C for 48 hrs 
aHoldeman and Moore, 1975. 
bMcCann, et al., 1996,. 
cDifco Laboratories, Detroit, MI. 
d3M Microbiology Products, St. Paul, MN. 
eOxoid limited, Hampshire, England. 
f Marshall, 1992. 
gNCCLS, 2001. 
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mL of salt solution.  Resazurin (Sigma-Aldrich) solution was prepared by dissolving 100 mg in 
100 mL distilled water.  The medium was boiled then cooled, and 5 g/L L-cysteine (Sigma-
Aldrich) was added under a constant flow of CO2.  Media was under a flow of CO2 until media 
turned from pink to colorless.  Media was then transferred to the anaerobic chamber and used for 
fecal processing.  
Phosphate and magnesium chloride dilution water was prepared as previously described 
(Marshall, 1992).  Stock phosphate solution was prepared by dissolving 34 g KH2PO4 in 500 mL 
distilled water, pH adjusted to 7.2 with 1 N NaOH, the volume brought up to 1 L with distilled 
water, and sterilized at 121°C for 15 min.  Stock MgCl2 solution was prepared by dissolving 38 g 
MgCl2 (Sigma-Aldrich) in 1 L distilled water, and autoclaved at 121°C for 15 min.  Stock 
solutions were stored at 4°C until use.  Class C dilution water was prepared by the addition of 
1.25 mL stock phosphate solution and 5 mL MgCl2 solution, and the volume brought up to 1 L 
with distilled water.  The pH was adjusted to 7.4 (pH 7.2 after autoclaving).  Media was 
dispensed in aliquots of 10.2 mL into tubes or 105 mL into bottles (to achieve 9.9 and 99 mL 
blanks after autoclaving, respectively).  Dilution blanks were then autoclaved for 15 min for 
tubes, or 30 min for bottles at 121°C.  Brucella stearothermophilus, BT Sure biological indicator 
for steam sterilization (Barnstead/Thermolyne, Inc., Dubuque, IA), was used as an indicator of 
sterility.  Spores were autoclaved with the media then incubated at 55°C for 24 hr.  Lack of 
growth indicated the autoclave was working properly. 
For the enumeration of Bifidobacter species, BS-LV agar was prepared as previously 
described (McCann et al., 1996).  To each liter of Liver Veal agar (Difco), 5 g propionic acid 
sodium salt (Eastman Kodak Company, Rochester, NY), 10 g α-lactose (Sigma-Aldrich), 500 
mg lithium chloride (Sigma-Aldrich), 400 mg L-cysteine, and 20 mg sodium lauryl sulfate 
(Sigma-Aldrich) were added before autoclaving at 121°C for 15 min.  Media was tempered to 
48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated with approximately 10 mL of BS-
LV.  After solidifying, an additional 10 mL of agar was overlaid and allowed to solidify.  
Finally, an additional 10 mL of BS-LV plus neomycin sulfate solution was overlaid and allowed 
to solidify before incubation.  Neomycin sulfate (Sigma-Aldrich) was prepared by dissolving 100 
mg in 6.7 mL sterile distilled water and frozen in 0.5 mL amounts.  Just prior to use, 9.5 mL 
sterile distilled water was added and mixed.  For every 175 mL of BS-LV agar 1 mL of 
neomycin solution was added.   
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Campylobacter Agar Base (Karmali; Oxoid, Hampshire, England) was supplemented 
with freeze-dried Campylobacter Selective Supplement SR167E (Karmali; Oxoid).  One vial of 
supplement contained 50 mg sodium pyruvate, 16 mg cefoperazone, 10 mg vancomycin, and 50 
mg cyclohexamide.  Vial components were dissolved by 2 mL of 50% ethanol and aseptically 
added to every 500 mL of sterile Campylobacter Agar Base.  Karmali agar was used for the 
enumeration of Campylobacter coli and C. jejuni at 42°C.  Samples (0.1 mL) were plated in 
duplicate using the spread plate method. 
Oleandomycin Polymyxin Sulphadiazine Perfringens Agar (OPSP) was used for the 
enumeration of Clostridium perfringens.  Perfringens Agar Base (OPSP; Oxoid) was mixed and 
autoclaved at 121°C for 15 min.  Sterile agar was supplemented with freeze-dried Perfringens 
Selective Supplements A and B (OPSP; Oxoid).  One vial of Supplement A (SR076E) contained 
50 mg of sodium sulphadiazine and was dissolved in 2 mL of sterile distilled water.  One vial of 
Supplement B (SR077E) contained 0.25 mg oleandomycin phosphate and 5000 I. U. polymyxin 
B sulphate, and was dissolved in 2 mL sterile distilled water.  One vial of Supplement A plus one 
vial of Supplement B were added to each 500 mL of sterile Perfringens Agar Base.  Medium was 
tempered to 48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated with approximately 
15 mL of medium. 
Rogosa SL Agar (Difco) was used for the enumeration of Lactobacillus.  Agar was 
mixed, steamed for 30 min, and supplemented with 1.32 mL/L 12 N glacial acetic acid (Sigma-
Aldrich) and adjusted to a final pH of 5.4.  Medium was tempered to 48°C and 0.1 to 1 mL of 
sample (in duplicate) was pour plated with approximately 15 mL of medium. 
RCM was used for the enumeration of anaerobic bacteria to acquire a Total Anaerobe 
Count.  Medium was tempered to 48°C and 0.1 to 1 mL of sample (in duplicate) was pour plated 
with approximately 15 mL of medium. 
E.coli/Coliform Petrifilm (3M Microbiology Products, St. Paul, MN) was used for the 
enumeration of E. coli and Total Coliform counts.  Samples (1 mL) were plated in duplicate.  
Blue colonies with gas were read as positive for E. coli.  Red colonies with gas were counted as 
other coliforms.  Blue colonies with gas plus red colonies with gas were considered to be a Total 
Coliform count.   
Fecal samples.  Swine feces were obtained from four Landrace X Yorkshire crossbred 
barrows.  They were 5 months of age, weighed between 80 and 90 kg, and were housed at the 
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University of Kentucky Animal Laboratory.  The diet consisted of 85% corn, 12% dehulled 
soybean meal, 1% dicalcium phosphate, and less than 1% of limestone, slat, vitamin and mineral 
mix.  They were receiving no antibiotics.  Pigs were kept in individual 5’ x 10’ pens with slatted 
floors, continuous lighting, and a constant temperature of approximately 25°C.  Water was 
available ad libitum.  Fresh stool samples were obtained, placed in four separate plastic bags, and 
were delivered into the anaerobic chamber within 10 min of collection for processing.  
Anaerobic chamber was under a CO2 environment in the absence of O2. 
Equal weights of feces from each pig were pooled and blended with anaerobic dilution 
solution in a Waring blender for 60 seconds to achieve a 10% (w/v) fecal slurry.  Aliquots of 50 
mL fecal slurry were transferred into 125-mL serum bottles under a constant flow of CO2.   
In vitro treatments and inoculum.  Treatments were in a 4 x 2 factorial arrangement and 
included type of compound (factor A) and C. perfringens inoculum strain (Factor B).  Treatment 
combinations are presented in Table 10.  Each treatment had 3 replicates.  
Carbadox (Sigma-Aldrich) was prepared under a sterile laminar flow hood (UV light for 
15 min).  A volume of 40 mL of 95% ethanol (0.2 µm filtered) was mixed with 0.12 g carbadox.  
The tubes were mixed and stored in 40 mL Fisherbrand (Fisher) plastic tubes surrounded by 
aluminum foil at 4°C.   
CFA and CGA stock solutions contained 26 mg/mL and were solubilized in 70% ethanol.  
Stock solution (1 mL) was added to the appropriate serum bottle containing 50 mL fecal slurry 
and 1 mL of inoculum.   
Serum bottles were prepared under a constant flow of CO2 using gas jets.  Each bottle 
was adjusted to contain 1.346% ethanol and was sealed by a butyl rubber stopper then crimp-
sealed.   
Clostridium cultures were transferred twice in Cooked Meat Medium and incubated 
anaerobically for 24 hr at 37°C.  The cultures were then streaked onto RCM with 1.5% agar and 
incubated anaerobically for 24 hr at 37°C.  Cultures were suspended in sterile dilution water to 
achieve 0.5 McFarland Standard, and 1 mL of the appropriate culture was anaerobically 
transferred into sealed serum bottles using sterile 1-mL syringes.  After the addition of the 
compounds and inoculum, serum bottles were incubated in a shaking water bath at 125 rpm for 
24 hr at 39°C. 
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Table 10.  List of in vitro treatments and inoculum used in this study. 
Treatment Inoculuma Compound 
A None None 
B 92Db None 
C 92Gc None 
D 92D CFAd 
E 92G CFA 
F 92D CGAe 
G 92G CGA 
H 92D Carbadoxf 
I 92G Carbadox 
a Inoculum level approximately 2 x 106 bacteria per mL 
bCulture 92D = Clostridium. perfringens University of Kentucky isolate from poultry. 
cCulture 92G= C. perfringens ATCC 13124. 
dCFA = 500 ppm caffeic acid. 
eCGA = 500 ppm chlorogenic acid. 
fCarbadox = 15 ppm Carbadox. 
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Chemical analysis.  Samples were taken at 0, 0.75, 1.5, 2.5, 4, 6, 12, and 24 hr.  A 
volume of 1 mL was removed anaerobically from each serum bottle with a syringe and 
centrifuged for 5 min at 20,800 x g (Eppendorff Centrifuge 5417C, Brinkman Instruments, Inc., 
Westbury, NY).  The supernatant was drawn off, placed in storage vials, and stored at a 
temperature of -20°C until further analysis.  
Lactate was analyzed by an enzymatic method using lactate dehydrogenase (Hohorst, 
1965).  For every 50 assays, the lactate premix contained 1.42 g hydrazine sulfate (Nutritional 
Biochemicals Corporation, Cleveland, OH), 2.1 g glycine (Sigma-Aldrich), 0.056 g Na2-
EDTA•2H2O  (Fisher) dissolved in 14 mL distilled water, and 20 mL 2 N NaOH.  The pH of the 
premix was adjusted to 9.5 using 1 N NaOH, and 84 mg β-Nicotinamide Adenine Dinucleotide 
(β-NAD; Sigma-Aldrich) and 200 U lactate dehydrogenase (Sigma-Aldrich) were added.  
Samples were thawed and 50 µL dispensed into glass tubes (in duplicate).  A standard curve was 
prepared using 4.44 mM lactate standard (Sigma-Aldrich).  Premix (1 mL) was added, tubes 
were gently mixed and incubated 45 min at room temperature.  Absorbance was read at 340 nm.  
The maximum absorbances (λmax) at pH 9.5 are 329 nm for CFA and 346 nm for CGA 
(Friedman and Jürgens, 2000).  The λmax of the compounds at pH 9.5 allows for interference with 
the lactate assay read at 340 nm.  A standard curve was prepared using 500 ppm CFA and CGA 
stock solutions. 
To confirm the presence or absence of lactate, high pressure liquid chromatography 
(HPLC) was used.  A Sulpelcogel™ H HPLC Column (25 cm x 4.6 mm; Sulpelco, Bellefonte, 
PA) was run at 30°C using 0.1% phosphoric acid as the eluent at a rate of 0.17 mL/min on a 
Ranin HPXL solvent delivery system (Ranin Instrument Co., Inc., Woodburn, MA).  A lactate 
standard (50 µL of 4.44 mM) was eluted to serve as a control.  
Volatile fatty acids were analyzed by gas chromatography (Supelco, Inc., 1985; Gow 
Mac chromatograph model 580 equipped with a Supelco 1000 column [1% H3PO4, 100/120 
mesh]).  Samples were thawed, 400 µL dispensed into centrifuge tubes, and 125 µL of 25% 
meta-phosphoric acid (Fisher) was added.  Samples were centrifuged for 7 min at 20,800 x g, 
and 500 µL of clarified sample was dispensed into Wheaton GC vials before analysis. 
Initial slurry pH and final pH (time 0 and 24 hr) readings were recorded using Accumet 
pH Meter 930 (Fisher). 
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Differentiation of C. jejuni.  In order to differentiate between C. coli and C. jejuni, the 
hippurate reaction was observed.  Individual colonies were picked from Karmali agar.  The 
colonies (18 total, 10 and 8 from each plate) were from the 10-5 dilution of the initial fecal slurry.  
They were each suspended in 5 mL of BB, streaked onto s-BBA, and incubated for 48 hr at 42°C 
in a microaerophilic incubator.  The resulting colonies were then tested for the hippurate reaction 
(in duplicate) according to methods previously described (BAM, 1998).  Approximately 2 mm 
loopfull of the culture was suspended in 0.4 mL of a 1% sodium hippurate solution and 
incubated for 2 hr in a 37°C water bath.  Sodium hippurate (Sigma-Aldrich) solution was 
prepared by dissolving 0.1 g in 10 mL distilled water and filter sterilized (0.2 µm pore size, 
Millipore).  After incubation, 0.2 mL of 3.5% ninhydrin reagent (1, 2, 3-triketohydrindene) was 
added, agitated, and incubated for an additional 20 min.  Ninhydrin reagent (R47; Eastman 
Kodak) was prepared by dissolving 3.5 g in 100 mL of a 1:1 mixture of acetone (Fisher) and 1-
butanol (Fisher).  Campylobacter jejuni ATCC 33291 was used as the quality control organism.  
A color change to deep violet was considered a positive reaction.   
Statistical analyses.  Data were analyzed as a 4 x 2 factorial in a completely randomized 
design using PROC GLM of SAS (1988).  Treatment combinations defined grouped, structured 
populations, and the Bonferroni t-test for nonorthogonal contrasts was used to determine 
differences between treatments.  One serum bottle was the experimental unit, with 3 replicates 
per treatment.  Bacterial counts were converted to logarithm units (log10) before statistical 
analysis.  Bacterial counts were analyzed at 24 hr, while VFA concentrations were analyzed at 
each time point.  Correlations between bacterial counts at 24 hr were analyzed using the PROC 
CORR procedure of SAS.  Correlations between bacterial counts at 24 hr and VFA 
concentrations at 24 hr were analyzed using the PROC CORR procedure using the Pearson and 
Spearman options.   
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CHAPTER 5 
Results and Discussion 
 
Methods development 
Some preliminary work was required to develop the methods to be used for the main 
studies.  The National Committee for Clinical Laboratory Standards methods for macrobroth 
dilution technique (NCCLS, 2000), agar dilution technique (NCCLS, 2001), and the in vitro 
incubation were of concern.  The results are discussed in more detail in Chapter 3, and will only 
be briefly summarized in the following paragraphs. 
Two bacterial cultures were eliminated in Study 1.  Salmonella enteritidis 108A and 
Escherichia coli ATCC 25404 were not able to survive in broth containing 3% ethanol.  The 
alcohol interfered with the macrobroth dilution technique when trying to determine the MICs of 
alcohol soluble antimicrobials.   
Study 2 determined that blood should not be used in agar dilution plates for determining 
MICs.  Components in the blood interacted with CFA and CGA, preventing the compounds from 
inhibiting bacterial growth.  This is a problem when attempting to determine MICs, giving false 
results.  Staphylococcus aureus grew well on MHA with 7% ethanol.  Clostridium perfringens 
grew well on all agars containing 7% ethanol except for RCM.  This suggested that type of 
media influenced growth when agar contained ethanol. 
Study 3 resolved the best combination of media to use for growth of cultures and for agar 
dilution plates used for testing MICs.  Ethanol concentration is a concern when using an agar 
dilution method (compared to broth).  Growth of C. perfringens was supported when RCM was 
used as the source agar then transferred to BA containing 3.5% ethanol.  This determined type of 
media to be used for the MICs of the compounds on C. perfringens cultures.  Campylobacter 
jejuni growth was inhibited on all agars containing 3.5 and 7% ethanol, and required further 
investigation. 
Study 4 demonstrated that C. jejuni growth was supported on agar containing less than or 
equal to 1.5% ethanol.  C. jejuni grew well on source agar  s-BBA with no ethanol, and BA with 
1.5% ethanol.  For MIC testing, s-BBA was chosen as the source agar.  Since hemin and vitamin 
K1 do not interfere with determining the MICs, s-BA was chosen for agar dilution testing.  
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However, another limiting factor emerged when CFA would not solubilize.  Despite the visibly 
insoluble compound, CFA inhibited C. jejuni at 480 ppm. 
Study 5 further defined specific media formulations to be used in MIC testing of C. 
jejuni.  It was determined that 0.5 mL of CFA and CGA stock solutions solubilized in 60% 
ethanol were to be used in agar dilution medium.     
One final problem arose during a preliminary in vitro incubation.  Campylobacter did not 
survive the incubation period when swine feces were introduced.  This complication could not be 
addressed satisfactorily, indicating that this particular in vitro method was not adequate to study 
Campylobacter dynamics within the microbial ecology of swine feces.   
 
Minimum inhibitory concentrations 
 A summary of results can be found in Table 11.  While several studies exist on the 
antimicrobial nature of CFA, there are few that examine CGA.  All Gram-positive organisms 
were affected by CFA, and all but one was affected by CGA.  Three of the four S. aureus 
cultures were inhibited by 100 ppm CFA and 500 ppm CGA.  The remaining S. aureus ATCC 
43300 is a methicillin- and oxacillin-resistant strain that required 200 ppm CFA and 500 ppm 
CGA for inhibition.  Both C. perfringens cultures were inhibited by 300 ppm CFA.  However, 
the toxin producing strain C. perfringens ATCC 13124 was not susceptible to 1000 ppm CGA.  
Yet, the other C. perfringens strain isolated from poultry was inhibited by 400 ppm CGA.  These 
results agree with other studies where S. aureus and C. perfringens were inhibited by CFA 
(Debrauwer et al., 1989; Tunçel and Nergiz, 1993; Binutu et al., 1996; Lee et al., 2001). 
In this study, Gram-negative organisms (E. coli, Salmonella, and Campylobacter) were 
not susceptible to 1000 ppm CFA or CGA.  Two other studies concurred with these findings.  E. 
coli and Pseudomonas aeruginosa were not inhibited by 500 ppm CFA (Debrauwer et al., 1989).  
CFA was solubilized in DMSO, and a microplate method with nutrient broth was used.  In 
another study, E. coli was not inhibited by CFA using methanol as a solvent (Lee et al., 2001).  A 
disk diffusion assay on Eggerth-Gagnon (EG) agar was the method used.   
Other studies that reported inhibition of Gram-negative organisms used different 
solvents, media, or MIC methods.  When inhibition was successful, common methods between 
the studies included using water as the solvent (Aziz et al., 1998; Tsou et al., 2000), use of 
trypticase soy broth or agar (Herald and Davidson, 1983; Tunçel and Nergiz, 1993; Tsou et al.,  
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Table 11.  Minimum inhibitory concentrations (µg/mL) of caffeic acid and chlorogenic 
acid. 
Culture Caffeic acid 
Chlorogenic 
acid 
   
Escherichia coli 
ATCC 11775 
NI NI 
Escherichia coli 
ATCC 25922 
NI NI 
Escherichia coli 
ATCC 43895 
NI NI 
Salmonella typhimurium 
ATCC 13311 
NI NI 
Salmonella typhimurium 
ATCC 700408 
NI NI 
Salmonella spp. 
TT42 
NI NI 
Campylobacter jejuni 
ATCC 33291 
NI NI 
Staphylococcus aureus 
ATCC 12600 
100 500 
Staphylococcus aureus 
ATCC 25923 
100 500 
Staphylococcus aureus 
ATCC 27543 
100 500 
Staphylococcus aureus 
ATCC 43300 
200 500 
Clostridium perfringens 
ATCC 13124 
300 NI 
Clostridium perfringens 
92D 
300 400 
aNI = No inhibition 
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2000), and a broth dilution method (Herald and Davidson, 1983; Tsou et al., 2000).  Tsou et al. 
(2000) were also able to inhibit Shigella with CGA. 
The pH of the media can also have an affect.  Herald and Davidson (1983) found that S. 
aureus was 46% more inhibited by 1000 ppm CFA in broth at pH 7 compared to pH 6.  In the 
same study, E. coli was 16% more inhibited at pH 6 compared to pH 7.  The media used in this 
study for MIC testing were MHB (pH 7.3) and BA (pH 7), and could be a factor contributing to 
the susceptibility of Gram-positive bacteria and the resistance of the Gram-negative bacteria to 
the compounds.  The pH determines the chemical nature of the compound, affecting polarity and 
solubility, along with ability to inhibit some microorganisms (Baranowski and Nagel, 1982). 
One interesting observation occurred when C. jejuni initially appeared to be susceptible 
to 480 ppm CFA.  This transpired during the methods development (Study 4, Chapter 3).  Later, 
C. jejuni was completely insensitive to 1000 ppm CFA.  The major difference was the percent 
ethanol used as a solvent.  Initially, 28% ethanol was used, while 60% ethanol was used later 
(1.4 and 1.5% ethanol in agar, respectively).  This suggests that water solubility played a role in 
inhibition for this particular microorganism.  This agrees with the studies that used water as a 
solvent and were able to inhibit Gram-negative organisms (Aziz et al., 1998; Tsou et al., 2000).  
However, Tunçel and Nergiz (1993) solubilized CFA in 95% ethanol and were able to inhibit 
Gram-positive and Gram-negative bacteria, but used an agar dilution method with trypticase soy 
agar.  As supported by the findings of Stern et al. (1988), type of media my play a critical role in 
determining susceptibility to antimicrobials.   
 
In vitro incubation 
 Results from the MIC testing revealed that concentrations of 500 ppm of CFA and CGA 
were sufficient to inhibit most Gram-positive organisms.  This level was then chosen for the 
CFA and CGA treatments in the in vitro incubation.   
 Upon statistical analysis, data were consistent with the absence of interactions between 
type of compound (factor A) and C. perfringens inoculum strain (factor B).  Therefore, data were 
pooled according to type of compound and analyzed as a one-way classification of treatments.  
Treatment A was the control and contained no compound (A, B, and C pooled), treatment B 
contained 500 ppm CFA (D and E pooled), treatment C contained 500 ppm CGA (F and G 
pooled), and treatment D contained 15 ppm carbadox (H and I pooled). 
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Carbadox is used as a growth promoter in swine, and its use has been banned by the 
European Union (EC, 1998b).  Many studies have been done on the ability of carbadox to 
improve growth performance and the prevention or treatment of swine dysentery (Yen and Pond, 
1993; Raynaud et al., 1981).  Carbadox is thought to promote growth by reducing the mass of the 
small intestines, thereby decreasing maintenance energy  (Yen et al., 1987).  Few studies are 
available on the effect of carbadox on the microbial ecology of the gut.  White et al. (2002) 
studied microbial populations in the pig in vivo, but found no differences between the basal diet 
and carbadox supplementation on Bifidobacteria, lactobacilli, E. coli, coliforms, total 
aerotolerant anaerobes, Salmonella, or C. perfringens counts in feces. 
Effect of treatment on bacterial counts.  Counts from all populations except 
Bifidobacteria were reduced by approximately 1 log after 24 hr of incubation.  This can be 
explained by the lack of substrate in the medium used for the fecal slurry and accumulation of 
VFAs that inhibit some bacteria.  The analysis of variance for bacterial counts are presented in 
Figures 9-15. 
 Treatment containing CGA, CFA, and carbadox had lower total aerotolerant anaerobe 
counts than the control (9.3, 9.4, and 9.7 versus 10.3 log, p<0.0001; Figure 9).  CFA, CGA, and 
Carbadox were not different from each other (p>0.12).  Although there were statistical 
differences, a reduction of 1 log is required to be considered to microbiologically important.  
There was a 0.6 log reduction for Carbadox, 0.9 log reduction for CGA, and a 1 log reduction in 
the CFA treatment.  There was a very high, positive correlation (r >0.8, p<0.05) between total 
anaerobe and Bifidobacteria counts in the control (r=0.87605), CFA treatment (r=0.90116), and 
carbadox treatment (r=0.99514).  In other words, 77, 81, and 99% of the variation in total 
anaerobe counts can be explained by the variation in Bifidobacteria counts in the control, CFA, 
and carbadox treatments, respectively.  However, this does not establish a cause and effect 
between the two counts.   
Treatments containing CGA, CFA, and carbadox had lower Bifidobacteria counts than 
the control (9.2, 9.4, and 9.7 versus 10.3 log, p<.0001; Figure 10).  However, the three treatments 
were not different from one another (p>0.08).  The differences between the control and the 
treatments were 0.6 log reduction for carbadox, 0.9 log reduction for CFA, and 1.1 log reduction 
for CGA.  This contradicts the findings of Lee et al. (2001) where Bifidobacteria were not  
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Figure 9.  Total Aerotolerant Anaerobe counts (log10 CFU/g) from the in vitro incubation at 
24 hours.  Bars represent + standard error (SE) of the mean.  Treatments with the unlike letters 
were different (p<0.0001).  Treatments included control with no compound (Control), 500 ppm 
caffeic acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 10.  Bifidobacteria counts (log10 CFU/g) from the in vitro incubation at 24 hours.  
Bars represent + standard error (SE) of the mean.  Treatments with the unlike letters were 
different (p<0.0001).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 11.  Lactobacilli counts (log10 CFU/g) from the in vitro incubation at 24 hours.  Bars 
represent + standard error (SE) of the mean.  Treatments with unlike letters were different 
(p<0.01).  Treatments included control with no compound (Control), 500 ppm caffeic acid 
(CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 12.  Total Coliform counts (log10 CFU/g) from the in vitro incubation at 24 hours.  
Bars represent + standard error (SE) of the mean.  Treatments with the unlike letters were 
different (p<0.0001).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 13.  Escherichia coli counts (log10 CFU/g) from the in vitro incubation at 24 hours.  
Bars represent + standard error (SE) of the mean.  Treatments with the unlike letters were 
different (p<0.001).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 14.  Percentage of Escherichia coli present in Total Coliform counts from the in vitro 
incubation at 24 hours.  Bars represent + standard error (SE) of the mean.  Treatments with the 
same letter are not different (p=0.16).  Treatments included control with no compound (Control), 
500 ppm caffeic acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Figure 15.  Clostridium perfringens counts (log10 CFU/g) from the in vitro incubation at 24 
hours.  Bars represent + standard error (SE) of the mean.  Treatments with like letters were not 
different (p>0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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inhibited by CFA.  Perhaps CFA and CGA metabolites created by other bacteria were toxic to 
the Bifidobacteria in this study.  
For lactobacilli counts, there was one replicate from the control where no colonies grew.  
No growth was observed on the 10-7 dilution, and lower dilutions were not plated.  Therefore, 
that replicate was excluded from analysis.  The treatment containing CGA had lower lactobacilli 
counts than the control (8.2 versus 9.1 log, p<0.01; Figure 11).  However, there were no 
differences between CGA, CFA, and the carbadox treatments (8.2, 8.6, and 8.7, p>0.18).  Again, 
Lee et al. (2001) found that Lactobacillus acidophilus was not susceptible to CFA, suggesting 
that some lactobacilli may be susceptible to CFA and CGA metabolites produced by other 
bacteria.  
Lactobacilli and Bifidobacteria are associated with beneficial effects on intestinal health.  
They interfere with adherence of pathogens to intestinal cells, elicit an immune response of the 
host, produce chemicals that inhibit the growth of pathogens, and restore the ecological balance 
of normal intestinal flora (Sullivan and Nord, 2002).  Reduced counts of these bacteria have been 
related to sick animals (Robinson et al., 1984). 
 The treatment containing carbadox had lower total coliform counts than CFA, CGA, and 
the control (5.2 versus 5.6, 5.8, and 5.9 log, p<0.0001; Figure 12).  However, there was only a 
0.7 log reduction.  White et al. (2002) were able to lower coliforms counts with carbadox in the 
jejunum and cecum of the pig by 0.9 and 1.3 logs, but did not have the same results when 
analyzing fecal swab samples.  Coliforms are non-spore-forming, Gram-negative, rod-shaped 
bacteria that ferment lactose and produce gas and acid.  They are often used as an indicator of the 
potential presence of pathogens (Rompré et al., 2002). 
 The treatments containing carbadox and CFA had lower Escherichia coli counts than 
CGA and the control (4.7 and 4.9 versus 5.2 and 5.3 log, p<0.001; Figure 13).  The CFA and 
carbadox treatments were not different from each other (p>0.35).  The CGA treatment and the 
control were not different from each other as well.  In this study E. coli were not inhibited by the 
compounds during MIC testing, and responded differently to the in vitro incubation.  This could 
be due to type of media used for MIC testing (previously discussed).  There was a very high, 
positive correlation between E. coli and total coliform counts in the control (r=0.89071) and 
carbadox treatments (r=0.88492).  Escherichia coli are thermotolerant bacteria and are a part of 
the natural flora of the intestine, and is known as a fecal coliform (Rompré et al., 2002).  Many 
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different strains are associated with foodborne illnesses (Levine, 1987) and diarrheal diseases in 
swine (Shu et al., 2001). 
The treatment containing CFA had lower percentages of E. coli in total coliform counts 
than CGA, the control, and carbadox (18.9 versus 25.1, 26.3, and 31.2%, p<0.01; Figure 14).  
The control, CGA, and carbadox treatments were not different from each other (p>0.09).  
Percentage of E. coli was used to study the dynamics of a section of the coliform population.  A 
reduced percentage means that the proportion of other coliforms increased.  The significance of 
this observation is beyond the scope of this study.   
There were no differences in Clostridium perfringens counts between the control, CFA, 
CGA, and carbadox treatments (2.7, 2.6, 2.5, and 2.4 log, p=0.37; Figure 15).  Despite the ability 
of CFA and CGA to inhibit growth of C. perfringens during the MIC testing in this study and by 
Debrauwer et al. (1989), in vitro there appeared to be no susceptibility to the compounds.  This 
suggests that C. perfringens is not susceptible to the metabolic end products of CGA and CFA.  
C. perfringens produces toxins and causes foodborne illness in humans (Shandera et al, 1983) as 
well as depressing swine growth performance in livestock (McDonel, 1980; Strauch, 1987c). 
Three colonies survived the in vitro incubation on Karmali Agar, selective for C. jejuni 
and C. coli at 42°C.  After a Gram stain procedure, the surviving colonies were determined to be 
Gram-positive cocci.  Since Campylobacter are Gram-negative rods, the surviving colonies were 
ruled out, concluding that Campylobacter did not survive the in vitro incubation.  Because of the 
bacterium’s fastidious nature, few studies have been done to determine the average number of 
Campylobacter found in feces.  Weijtens et al. (1999) found a variation in counts between pigs, 
ranging from less than 630 CFU/g feces up to 3.6 x 106 CFU/g.  In this study, it was determined 
that there were nearly 8 x 105 CFU/g in swine feces (fresh wet weight), but were not able to 
survive the in vitro incubation. 
 The hippurate reaction was used to differentiate C. coli from C. jejuni in the initial fecal 
slurry.  The control strain produced a clear, deep violet reaction, testing positive as C. jejuni.  
Ten and 8 colonies were isolated from two 10-5 dilution plates.  All eighteen colonies tested 
negative.  Nielsen et al. (1997) found that 95% of thermophilic campylobacter in swine feces 
were identified as C. coli, where C. jejuni only accounted for 4%.  Relative to this study, an 
estimated 3.2 x 104 CFU/g were C. jejuni.  
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 Effect of treatment on volatile fatty acids.  Volatile fatty acids (VFAs) are end products 
of microbial metabolism, and may provide an indication of microbial activity in the intestinal 
tract.  They also serve as an energy source to the host animal.  The analysis of variance for VFAs 
is presented in Figures 16-23. 
 Acetate concentrations remained lower for the carbadox treatment throughout the 
incubation (Figure 16).  At 24 hr, the treatment containing CGA had higher acetate levels than 
the control and CFA treatment (40.3 versus 38.6 and 38.6 mM, p<0.0001), and the carbadox 
treatment had lower acetate levels than the control, CFA, and CGA treatments (31 versus 38.6, 
38.6, and 40.3 mM, p<0.0001).  There was no difference between the control and the CFA 
treatment (p=1.0)).  One explanation for higher amounts in the CGA treatment could be that 
CGA was used as an electron sink for acetogenesis (Sunvold et al., 1995; Weimer, 1998).  
Excess H2 can be deposited onto CGA metabolites (Imkamp and Müller, 2002).  The reduction 
in available H2 can cause a shift in fermentation, decreasing the carbon flow into succinate, 
ethanol, and lactate while increasing the flow to acetate (Wolin, 1975).  Acetate can then 
transported for use by muscle as an energy substrate (Jensen, 2001). 
At the end of the incubation, the treatment containing carbadox had lower propionate 
levels than the CFA and CGA treatments (8.9 versus 9.5 and 9.5 mM, p<0.01; Figure 17).  
However, the carbadox treatment was only 0.6 mM lower, and was not different from the control 
at 9.3 mM (p>0.07).  Plus, there were no differences between the three treatments at any other 
time point.  After absorption, propionate is transported to the liver and converted to glucose and 
used for energy.  Increased amounts of propionate are associated with increased production of 
animal protein (Wolin, 1981). 
 At 24 hr, the treatment containing carbadox had lower acetate:propionate ratios than the 
control, CFA, and CGA treatments (3.5 versus 4.1, 4.1, and 4.2 units, p<0.0001; Figure 18).  
This was due to the reduced acetate levels in the carbadox treatment.  CFA was not different 
from the control (p=0.73).  However, the CGA had higher acetate:propionate ratios than the 
control and CFA treatment (p<0.0001).  This was due to the increased acetate levels in the CGA 
treatment.  Acetate to propionate ratio has been used as a measure of reduction of Gram-positive 
cocci that produce acetate in ruminants (Weimer, 1998).  The change in ratio involves both 
reduction of acetate and increased propionate production.  This was not observed in this study.   
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Figure 16.  Acetate concentration (mM) trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 17.  Propionate concentration (mM) trends over time during the in vitro incubation.  
Mean +  standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 18.  Acetate to propionate ratio trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 19.  Butyrate concentration (mM) trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 20.  Valerate concentration (mM) trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 21.  Isobutyrate concentration (mM) trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<.05. 
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Figure 22.  Isovalerate concentration (mM) trends over time during the in vitro incubation.  
Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm chlorogenic acid;  
15 ppm carbadox; * p<0.05. 
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Figure 23.  Total volatile fatty acid concentration (mM) trends over time during the in vitro 
incubation.  Mean + standard error (SE).  ◊ Control;  500 ppm caffeic acid; ∆ 500 ppm 
chlorogenic acid;  15 ppm carbadox; * p<0.05. 
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Gram-negative as well as Gram-positive bacteria were reduced, and propionate production was 
not increased. 
 Butyrate concentrations remained lower for the carbadox treatment beginning at 2.5 hr 
(Figure 19).  At the end of the incubation, the carbadox treatment had lower butyrate levels than 
the control, CGA, and CFA treatments (7.7 versus 11.2, 11.3, and 11.5, p<0.0001).  The control, 
CFA, and CGA treatments were not different (p>0.18). The lower butyrate production resembles 
reduction of Gram-positive organisms in the rumen (Wolin, 1981).  In this study, selected Gram-
positive organisms were reduced, namely Bifidobacteria and lactobacilli.  Other bacteria may be 
stimulated to produce butyrate in the presence of excess acetate (Russell, 2002).  However, the 
transformation of excess acetate into butyrate in mixed cultures could also account for the 
increase in concentrations (Russell, 2002).  Butyrate is the preferred energy source of energy for 
colonic epithelial cells (Sunvold et al., 1995).  Reduced butyrate production by the carbadox 
treatment could help to explain the reduction of intestinal mass of swine. 
 At the end of the incubation, the carbadox treatment had lower valerate levels than the 
control, CGA, and CFA treatments (1.2 versus 1.5, 1.5, and 1.6 mM, p<0.0001; Figure 20).  The 
control, CFA, and CGA treatments were not different (p>0.14).   
There were no differences in isobutyrate levels between the control, CFA, CGA, and 
carbadox treatments (1.2, 1.3, 1.5, and 1.5 mM, p=0.2689; Figure 21).   
The treatment containing carbadox had lower isovalerate levels than CGA and CFA 
treatments (1.4 versus 1.5 and 1.5 mM, p<0.01; Figure 22), and there was no difference between 
the control and carbadox treatment (1.5 and 1.4 mM, p>0.58).  The control was also not different 
from the CGA and CFA treatments (p>0.09).  Still, isovalerate levels in the carbadox treatment 
were merely 0.1 to 0.2 mM lower, and may not be biologically important. 
Valerate, isobutyrate, and isovalerate are branched-chain fatty acids that are formed as a 
result of protein fermentation in the distal colon (Blaut, 2002).  Increased levels of these three 
compounds may indicate an increase in protein metabolism (Sakata et al., 1999).  Overall, 
valerate, isobutyrate and isovalerate concentrations increased through out the incubation, and 
was most likely due to microbial protein released from lysed cells.   
 The treatment containing carbadox had lower total VFA concentrations than the control, 
CFA, and CGA treatments (51.8 versus 63.2, 64.1, and 65.4 mM, p<0.0001; Figure 23).  This 
was mostly due to the lower acetate and butyrate concentrations in the carbadox treatment.  
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There were no differences between the control, CFA, and CGA treatments (p>0.06).  Total VFAs 
are a measure of overall microbial activity in the gut.  In addition to the ability of CFA, CGA, 
and CGA to effect microbial populations, they were able to effect the chemical aspect of the 
microbial ecology of swine feces.   
 pH analysis.  The pH at 0 and 24 hr are presented in Figure 24.  The pH was 6.5 for the 
initial fecal slurry at 0 hr.  At the end of the incubation, the pH of the control dropped by 0.1, 
while the CFA, CGA, and carbadox treatments were lowered by 0.2 units. 
Lactate analysis.  The control and the carbadox treatment showed a steady amount of 
lactate (0.3-0.6 mM) over the entire incubation (0 to 24 hr) as determined by the lactate assay.  
However, the CFA and CGA interfered with the assay, exhibiting higher amounts from 0.75 to12 
hr.  To determine the amount of lactate present without interference, HPLC was performed.  
Results demonstrated that lactate levels in the CFA and CGA treatments were consistently less 
than 1 mM for all time points (data not shown).  It can then be assumed that lactate 
measurements obtained from CFA and CGA treatments were due to CFA and CGA. 
The concentrations of CFA and CGA declined over time, and by 12 hr of incubation 
levels had diminished to below 1 mM for both compounds (Figure 25).  Reduction of the 
compounds over time was caused by microbial metabolism.  This is supported by several studies.  
Two strains of Streptococcus gallolyticus were able to decarboxylate caffeic acid (removal of 
COOH group) to produce the metabolite 4-vinylcatechol (Chamkha et al., 2002).  The phenolic 
acid decarboxylase (PAD) enzyme has been found in Lactobacillus plantarum, Pediococcus 
pentosaceus, Bacillus subtilis, and Bacillus pumilus (Barthelmebs et al., 2001), and was able to 
decarboxylate CFA.  The authors also suggest that PAD activity may be a stress response to 
avoid the toxicity of the compounds, though some species showed more enzyme activity than 
others did.  The strictly anaerobic bacterium Acetobacterium woodii was able to reduce a double 
bond in CFA (caffeate) to produce hydrocaffeate (3,4-hydroxyphenyl propionic acid) (Imkamp 
and Müller, 2002).  By using CFA as an electron acceptor, A. woodii was able to generate ATP.  
Besides decarboxylation and reduction, intestinal microflora can also dehydroxylate CFA 
(removal of OH group(s); Scheline, 1968; Chesson et al., 1999).  Other metabolic products of 
CFA from hind-gut fermentation include 4-ethylcatechol, 3-hydroxyphenylpropionic acid 
(3HPP), and 3-phenylpropionic acid (3PPA; Scheline, 1968; Chesson et al., 1999).   
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Figure 24.  pH measurements during the in vitro incubation. ◊ Control;  500 ppm caffeic 
acid; ∆ 500 ppm chlorogenic acid;  15 ppm carbadox. 
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Figure 25.  Disappearance of caffeic acid and chlorogenic acid for the in vitro incubation.  
Symbols represent caffeic acid (◊), and chlorogenic acid ( ). 
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The metabolic products of CFA can be further used by other intestinal microbes (cross-
feeding).  Phenylpropionic acid (PPA) increased the adherence of Ruminococcus albus to 
cellulose (Pegden et al., 1998), which encourages the breakdown of plant material in the gut.  
There are several pathways in which E. coli can metabolize 3-hydroxycinnamic acid (3HCI), 
PPA, and 3HPP (Díaz et al., 2001).  Metabolism involves breaking the aromatic (benzene) ring 
resulting in the production of succinic acid, acetyl-CoA, pyruvic acid, and fumaric acid.  These 
end products can then enter other metabolic pathways including the citric acid cycle to generate 
reducing equivalents (NADH) and energy (ATP; Moran et al., 1994b). 
Chlorogenic acid can also be metabolized by microbes.  Couteau et al. (2001) isolated 
Bifidobacterium lactis, two strains of Lactobacillus gasseri, and three strains of E. coli from 
human feces.  They demonstrated that these bacteria were able to hydrolyze CGA using the 
enzyme cinnamoyl esterase, producing CFA and quinnic acid.  Once CGA is hydrolyzed, CFA is 
available to be further metabolized by other microbes.   
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CHAPTER 6 
Summary  
 The objectives of this study were to determine the MICs of CFA and CGA against 
selected pathogens and to examine the effects of these compounds on the microbial ecology of 
swine feces.  However, the standard or established methods proved inconsistent and these 
methods had to be modified.   
 The standard method for testing MICs for aerobic bacteria was not able to support the 
growth of two Gram-negative bacteria in the presence of a low level of ethanol, and were 
excluded from further testing.  The standard method for testing the MIC for anaerobic and 
microaerophilic bacteria was used with the following adjustments: blood was not used in agar 
dilution plates, RCM was used as a source agar for C. perfringens, 1 mL of a 20x solution in 
70% ethanol was used in agar dilution plates for C. perfringens testing, and 0.5 mL of a 40x 
solution in 60% ethanol was used in agar dilution plates for C. jejuni testing.  For the in vitro 
incubation, the method used was unable to support the survival and growth of C. coli and C. 
jejuni in the presence of swine feces.   
Upon completion of the methods development, the MICs were determined.  CFA and 
CGA did not inhibit Gram-negative bacteria.  CFA inhibited Staphylococcus aureus ATCC 
12600, S. aureus ATCC 25923, and S. aureus ATCC 27543 at 100 ppm, S. aureus ATCC 43300 
at 200 ppm, and Clostridium perfringens ATCC 13124 and C. perfringens 92D at 300 ppm.  
Chlorogenic acid inhibited all four S. aureus strains at 500 ppm, and C. perfringens ATCC 
13124 at 400 ppm.  
The concentrations of CFA and CGA to be used for the in vitro incubation were based on 
the MIC results at 500 ppm.  The in vitro incubation examined specific bacterial populations and 
volatile fatty acid concentrations.  CFA lowered the counts of Bifidobacteria, coliforms, 
Escherichia coli, total anaerobes, and percent E. coli (p<0.01).  Percentage of E. coli was 12% 
lower than in the carbadox treatment.  CGA lowered Bifidobacteria, lactobacilli, and total 
anaerobe counts (p<0.01).  E. coli counts were 0.5 log higher than in the carbadox treatment, and 
percent E. coli was 6% higher than in the CFA treatment.  CFA did not affect VFA production 
(p>0.05).  CGA increased acetate concentrations by 1.7 mM (p<0.05).  Carbadox lowered the 
concentrations of acetate, propionate, butyrate, isovalerate, and total VFAs (p<0.01).  VFA 
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concentrations (excluding acetate) between caffeic and chlorogenic acid treatments were not 
different (p>0.05).  Both compounds disappeared by the end of incubation. 
 CGA is present in many foods, and can travel to the large intestines where it can inhibit 
microorganisms or be metabolized into CFA and quinnic acid.  CFA can then inhibit microbes or 
be metabolized by other gut microorganisms.  CFA had similar actions to carbadox in inhibiting 
some of the same bacteria.  A decreased number of pathogens may prevent disease, and a 
reduced bacterial load can lessen competition for nutrients with the animal.  At the same time, 
VFA production for the CFA treatment did not decrease, mainly due to acetate and butyrate 
concentrations.  Decreased pathogens and bacterial load without decreased VFA production 
could encourage the growth performance of swine. 
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APPENDIX 
Appendix Table 1.  Initial (0 hours) and final (24 hours) bacterial counts (log10 CFU/g†) from the in vitro incubation‡. 
Treatment C. jejuni 
Bifido-
bacteria  Lactobacilli  
Clostridium 
perfringens 
Escherichia 
coli  
Total 
Coliforms  %E. coli  
Total 
Anaerobes 
(Aerotolerant)
  (p<0.0001)  (p=0.0064)  (p=0..3693)  (p=0.0005)  (p=<0.0001)  (p=0.0081)  (p<0.0001) 
Initial 5.9 + 0.04 10.1 + 0.22 10.1 + 0.33 3.7 + 0.06 6.5 + 0.04  7.1 + 0.73 27.7+ 1.8 11.5 + 0.04
Final    
     Control 0 10.3 + 0.15 a 9.1 + 0.25 a 2.7 + 0.21 a 5.3 + 0.37 a 5.9 + 0.28 a 26.3 + 6.0 ab 10.3 + 0.20 a
     CFA 0 9.4 + 0.14 b 8.6 + 0.07 ab 2.6 + 0.29 a 4.9 + 0.07 bc 5.6 + 0.05 a 18.9 + 2.5 b 9.4 + 0.12 b
     CGA 0 9.2 + 0.43 b 8.2 + 0.60 b 2.5 + 0.31 a 5.2 + 0.09 ab 5.8 + 0.10 a 25.1 + 5.8 a 9.3 + 0.04 b
     Cbx 0 9.7 + 0.45 b 8.7 + 0.40 ab 2.4 + 0.35 a 4.7 + 0.17 c 5.2 + 0.14 b 31.2 + 0.1 a 9.7 + 0.42 b
†CFU/g = colony forming units per grams of feces (wet weight) + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
 
 
 99
Appendix Table 2.  Acetate concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.056)  (p=0.1425)  (p=0.0056)  (p=0.004)  (p<0.0001)  (p=0.0123)  (p<0.0001)  
Control 8.4 + 0.9 9.3 + 0.8 a 11.6 + 1.0 a 14.8 + 1.2 a 16.3 + 0.7 ab 19.5 + 0.9 a 26.6 + 1.4 a 38.6 + 0.7 a 
CFA 8.4 + 0.9 8.7 + 0.1 a 11.4 + 0.9 a 13.6 + 0.8 ab 15.9 + 0.9 ac 18.5 + 0.5 a 26.3 + 1.2 a 38.6 + 0.7 a 
CGA 8.4 + 0.9 10.0 + 1.0 a 12.7 + 0.2 a 14.9 + 0.2 a 17.2 + 0.6 b 19.5 + 1.2 a 27.1 + 3.5 a 40.3 + 1.0 b 
Cbx 8.4 + 0.9 9.0 + 0.7 a 12.0 + 1.2 a 13.2 + 0.3 b 14.9 + 0.4 c 15.9 + 0.4 b 22.8 + 0.6 b 31.0 + 0.5 c 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 3.  Propionate concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr 1.5 hr 2.5 hr 4 hr 6 hr 12 hr 24 hr
  (p=0.6383) (p=0.0207) (p=0.083) (p=0.0827) (p=0.0027) (p=0.843) (p=0.0076)
Control 4.7 + 0.2 5.3 +  1.3 a 5.8 + 0.3 a 7 + 0.5 a 7.1 + 0.3 a 7.8 + 0.2 a 8.2 + 0.5 a 9.3 + 0.2 ab 
CFA 4.7 + 0.3 4.8 + 0.04 a 5.8 + 0.3 a 6.6 + 0.2 a 7.1 + 0.3 a 7.5 + 0.2 ab 8.0 + 0.3 a 9.5 + 0.2 a  
CGA 4.7 + 0.4 5.2 +  0.3 a 6.2 + 0.1 a 6.9 + 0.1 a 7.4 + 0.2 a 7.6 + 0.4 ab 8.0 + 1.0 a 9.5 + 0.3 a 
Cbx 4.7 + 0.5 5.1 +  0.3 a 6.4 + 0.5 a 6.6 + 0.2 a 7.1 + 0.1 a 7.1 + 0.2 b 8.3 + 0.2 a 8.9 + 0.3 b 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).   Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 4.  Acetate to Propionate Ratio† at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.601)  (p=0.0025)  (p=0.0001)  (p<0.0001)  (p<0.0001)  (p<0.0001)  (p<0.0001)  
Control 1.8 + 0.1 1.8 + 0.3 a 2.0 + 0.06 a 2.1 + 0.04 ab 2.3 + 0.01 a 2.5 + 0.04 a  3.3 + 0.04 a 4.1 + 0.07 a 
CFA 1.8 + 0.2 1.8 + 0.01 a 2.0 + 0.05 ab 2.1 + 0.07 ac 2.2 + 0.04 b 2.5 + 0.01 a 3.3 + 0.02 a 4.1 + 0.01 a 
CGA 1.8 + 0.3 1.9 + 0.08 a 2.0 + 0.01 a 2.2 + 0.02 b 2.3 + 0.02 a 2.6 + 0.04 b 3.4 + 0.02 b 4.2 + 0.06 b 
Cbx 1.8 + 0.4 1.8 + 0.04 a 1.9 + 0.06 b 2.0 + 0.01 c 2.1 + 0.03 c 2.2 + 0.02 c 2.7 + 0.03 c 3.5 + 0.06 c 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).   Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 5.  Butyrate concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr 1.5 hr 2.5 hr 4 hr 6 hr 12 hr 24 hr  
  (p=0.0078) (p=0.0692) (p<0.0001) (p<0.0001) (p<0.0001) (p<0.0001) (p<0.0001)  
Control 3.1 + 0.1 3.1 + 0.03 a 3.8 + 0.2 a 4.9 + 0.3 a 5.2 + 0.2 a  6.2 + 0.2 a 8.3 + 0.5 a 11.2 + 0.2 a 
CFA 3.1 + 0.1 3.2 + 0.03 ab 3.8 + 0.2 a 4.5 + 0.2 a 5.2 + 0.2 a 6.0 + 0.2 a 8.3 + 0.4 a 11.5 + 0.2 a 
CGA 3.1 + 0.1 3.4 +  0.1 b 4.1 + 0.1 a 4.7 + 0.1 a 5.4 + 0.1 a 6.1 + 0.3 a 8.3 + 1.1 a 11.3 + 0.3 a 
Cbx 3.1 + 0.1 3.2 +  0.2 ab 3.8 + 0.3 a 3.9 +0.1 b 4.2 + 0.1 b 4.5 + 0.1 b 5.7 + 0.2 b 7.7 + 0.2 b 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).   Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 6.  Valerate concentrations (mM†) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.429)  (p=0.0012)  (p=0.0074)  (p=0.0107)  (p<0.0001)  (p=0.0002)  (p<0.0001)  
Control 0.5 + 0.03 0.5 + 0.04 a 0.5 + 0.02 a 0.6 + 0.03 a 0.7 + 0.05 a 0.9 + 0.04 a 1.3 + 0.09 a 1.5 + 0.06 a 
CFA 0.5 + 0.03 0.5 + 0.04 a 0.5 + 0.02 a 0.6 + 0.04 ab 0.7 + 0.02 ab 0.9 + 0.03 a 1.3 + 0.06 a 1.6 + 0.08 a 
CGA 0.5 + 0.03 0.5 + 0.02 a 0.5 + 0.01 a 0.6 + 0.01 ab 0.8 + 0.05 b 0.9 + 0.06 a 1.3 + 0.16 a 1.5 + 0.04 a 
Cbx 0.5 + 0.03 0.5 + 0.04 a 0.6 + 0.02 b 0.6 + 0.02 c 0.7 + 0.07 a 0.7 + 0.02 b 1.0 + 0.08 b 1.2 + 0.06 b 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 7.  Isobutyrate concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr 1.5 hr 2.5 hr 4 hr 6 hr 12 hr 24 hr
  (p=0.0277) (p=0.122) (p=0.4019) (p=0.0074) (p=0.2178) (p=0.3798) (p=0.2689)
Control 0.6 + 0.4 0.6 + 0.1 ab 0.8 + 0.3 a 1.1 + 0.2 a 1.2 + 0.1 a 0.9 + 0.3 a 0.9 + 0.2 a 1.2 + 0.2 a 
CFA 0.6 + 0.4 0.5 + 0.01 a  0.8 + 0.3 a 1.1 + 0.2 a 1.0 + 0.2 ab 0.7 + 0.1 a 0.8 + 0.1 a 1.5 + 0.1 a 
CGA 0.6 + 0.4 0.7 + 0.1 b 1.1 + 0.01 a 1.2 + 0.1 a 1.0 + 0.2 a 0.8 + 0.3 a 0.8 + 0.2 a 1.3 + 0.2 a 
Cbx 0.6 + 0.4 0.5 + 0.02 ab 1.0 + 0.3 a 1.2 + 0.03 a 0.8 + 0.2 b 0.6 + 0.02 a 1.0 + 0.2 a 1.5 + 0.4 a 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 8.  Isovalerate concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.001)  (p=0.0096)  (p=0.1726)  (p=0.088)  (p=0.0362)  (p=0.9899)  (p=0.0029)  
Control 0.7 + 0.05 0.6 + 0.004 a 0.7 + 0.06 a 0.8 + 0.06 a 0.8 + 0.06 a 0.9 + 0.06 a 1.1 + 0.09 a 1.5 + 0.05 ab 
CFA 0.7 + 0.05 0.6 + 0.01 a 0.7 + 0.04 a 0.8 + 0.04 a 0.8 + 0.03 a 0.8 + 0.03 ab 1.1 + 0.07 a 1.6 + 0.06 a 
CGA 0.7 + 0.05 0.7 + 0.03 b 0.7 + 0.01 ab 0.8 + 0.01 a 0.9 + 0.02 a 0.9 + 0.08 ab 1.1 + 0.14 a 1.5 + 0.07 a 
Cbx 0.7 + 0.05 0.6 + 0.03 ab 0.8 + 0.06 b 0.8 + 0.03 a 0.8 + 0.06 a 0.8 + 0.02 b 1.1 + 0.06 a 1.4 + 0.12 b 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).   Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 9.  Lactate and phenolic compound concentration (mM†) trends at various time points from the in vitro 
incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.429)  (p=0.0012)  (p=0.0074)  (p=0.0107)  (p<0.0001)  (p=0.0002)  (p<0.0001)  
Control 0.5 + 0.04 0.3 + 0.3 a 0.4 + 0.02 a 0.3 + 0.03 a  0.4 + 0.01 a 0.4 + 0.02 a 0.5 + 0.04 a 0.6 + 0.06 ac 
CFA 0.5 + 0.04 5.5 + 0.2 b 4.9  +  0.1 b 4.6  +  0.1 b 3.6  +  0.1 b 2.7  +  0.1 b 0.7 + 0.05 b 0.7  +  0.2 ac 
CGA 0.5 + 0.04 2.6 + 0.2 c 2.0  +  0.2 c 1.6  +  0.1 c 1.0  +  0.1 c 0.6 + 0.05 c 0.7 + 0.03 b 1.0 + 0.08 b 
Cbx 0.5 + 0.04 0.4 + 0.3 a 0.4 + 0.03 a 0.4 + 0.03 a  0.4 + 0.03 a 0.4 + 0.01 a 0.4 + 0.02 a 0.5  +  0.1 c 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 10.  Total volatile fatty acid concentrations (mM †) at various time points from the in vitro incubation‡. 
Treatment 0 hr 0.75 hr  1.5 hr  2.5 hr  4 hr  6 hr  12 hr  24 hr  
  (p=0.0718)  (p=0.0952)  (p=0.0113)  (p=0.0006)  (p<0.0001)  (p=0.0225)  (p<0.0001)  
Control 17.9 + 1.4 19.4 + 1.4 a 23.3 + 1.8 a 29.3 + 2.3 a 31.3 + 1.4 a 36.1 + 1.5 a 46.4 + 2.6 a 63.2 + 1.2 a 
CFA 17.9 + 1.4 18.2 + 0.2 a 23.1 + 1.7 a 27.1 + 1.4 a 30.6 + 1.5 ab 34.5 + 0.9 a 45.8 + 2.0 ab 64.1 + 1.3 a 
CGA 17.9 + 1.4 20.4 + 1.5 a 25.4 + 0.4 a 29.1 + 0.5 a 32.6 + 1.0 a 35.7 + 2.1 a 46.6 + 6.1 a 65.4 + 1.8 a 
Cbx 17.9 + 1.4 18.8 + 1.2 a 24.6 + 2.3 a 26.4 + .05 b 28.5 + 0.9 b 29.6 + 0.7 b 40.0 + 1.2 b 51.8 + 1.3 b 
†Mean + standard deviation (SD). 
‡Treatments with unlike letters were different (p<0.05).  Treatments included control with no compound (Control), 500 ppm caffeic 
acid (CFA), 500 ppm chlorogenic acid (CGA), and 15 ppm carbadox (Cbx). 
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Appendix Table 11.  Bacterial correlation coefficientsa (p<0.05) for the in vitro incubation at 24 hours. 
 Bifido-bacteria Lactobacilli 
C. 
perfringens 
Total 
Anaerobes E. coli 
Total 
Coliforms 
Controlb       
    Lactobacilli NSe      
    C.   
    perfringens 
NS NS     
    Anaerobes 0.87605 NS NS    
    E. coli NS NS NS NS   
    Coliforms NS NS NS NS 0.89071  
    % E. coli NS 0.74869 NS NS NS NS 
Caffeic acidc       
    Lactobacilli NS      
    C.  perfringens NS NS     
    Anaerobes 0.90116 NS NS    
    E. coli NS NS NS NS   
    Coliforms NS NS NS NS NS  
    % E. coli NS NS NS NS NS NS 
Chlorogenic acidc       
    Lactobacilli NS      
    C. perfringens NS NS     
    Anaerobes NS NS NS    
    E. coli NS 0.88866 NS NS   
    Coliforms NS NS NS NS NS  
    % E. coli NS NS NS NS NS NS 
Carbadoxd       
    Lactobacilli 0.88604      
    C. perfringens NS NS     
    Anaerobes 0.99514 NS NS    
    E. coli NS NS NS NS   
    Coliforms NS NS NS NS 0.88492  
    % E. coli NS NS NS NS NS NS 
a r > 0.8, very high correlation; 0.8 > r > 0.6,  substantial correlation.  
bdf=7, rcrit=0.666. 
cdf=4, rcrit=0.811 
ddf=3, rcrit=0.878. 
eNS, Not Significant, p>0.05. 
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Appendix Table 12.  Correlation coefficientsa (p<0.05, df=10, rcriet=0.576 ) between bacterial counts and 
volatile fatty acid concentrations for the in vitro incubation at 24 hoursd. 
 Bifido- bacteria 
Lacto- 
bacilli 
C. 
perfringens E. coli 
Total 
Coliform 
% E. 
coli 
Total 
Anaerobe 
Caffeic acid        
  Acetate NSb NS NS NS 0.77253 NS NS 
  Propionate NS NS NS NS 0.70268 NS NS 
  Acetate: 
   Propionate  NS
 NS NS NS NS NS NS 
  Butyrate NS 0.69464 NS NS 0.70009 NS 0.68571c 
  Valerate NS NS NS NS 0.66853 NS NS 
  Isovalerate NS 0.62462 NS NS 0.75822 NS 0.68571c 
  Isobutyrate NS NS NS NS 0.75685 NS NS 
  Total VFA NS NS NS NS 0.75533 NS 0.68571c 
Chlorogenic 
acid 
       
  Acetate NS NS NS -0.60152 -0.69209 NS 0.66288 
  Propionate NS NS NS -0.68571c NS NS 0.65714c 
  Acetate: 
   Propionate  NS
 NS NS NS NS NS NS 
  Butyrate NS NS NS -0.68571c -0.61283 NS 0.61339 
  Valerate NS NS NS NS NS NS NS 
  Isovalerate NS NS NS -0.65600 -0.66278 NS 0.59427c 
  Isobutyrate NS NS NS -0.70389 -0.71831 NS 0.59210 
  Total VFA NS NS NS -0.61253 -0.69597 NS 0.65740 
a r > 0.8, very high correlation; 0.8 > r > 0.6,  substantial correlation; 0.6 > r > 0.4, moderate correlation. 
bNS, not significant (p>0.05). 
cNon-linear correlation using Spearman option. 
dNone of the correlations from the control or the carbadox treatment were significant (p>0.05). 
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